CUMULATIVE SUPPLEMENT 10

JAN'88-OCT'88



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

8TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT

SUBSCRIBE NOW!

New 9th Edition



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

9TH EDITION

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- List of Drug Products Approved Under Section 505 of the Act by the Division of Blood and Blood Products
- Discontinued Drug Product List
- Orphan Drug Products with Exclusive Approval
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Biopharmaceutic Guidance Availability
- ANDA Suitability Petitions
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

F

APPROVED DRUG PRODUCTS

with

THERAPEUTIC EQUIVALENCE EVALUATIONS

8TH EDITION

CUMULATIVE SUPPLEMENT 11

NOVEMBER 1988

CONTENTS

APPROVED DRUG PRODUCTS

with

THERAPEUTIC EQUIVALENCE EVALUATIONS

8th EDITION

CUMULATIVE SUPPLEMENT 10

OCTOBER 1988

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 8th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products in the Division of Blood and Blood Products approved under Section 505 of the Act, and products discontinued from marketing or products which have had their approval withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products in the Division of Blood and Blood Products Approved Under Section 505 of the Act lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product, along with the application number and product number (FDA's internal file number). All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.] The effective date for the approved drug product (the earliest date a product may be marketed) appears, when appropriate, to the left of the approval date.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, List of Drug Products in the Division of Blood and Blood Products Approved Under Section 505 of the Act and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item. A newly approved product is also identified by a lozenge (◆) to the right of its strength which remains throughout all Cumulative Supplements for this edition.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, List of Drug Products in the Division of Blood and Blood Products Approved Under Section 505 of the Act and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line containing overstruck print. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print will remain in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the List of Drug Products in the Division of Blood and Blood Products Approved Under Section 505 of the Act and the Patent and Exclusivity Data will be dropped in subsequent Cumulative Supplements.

Products discontinued from marketing or products which have had their approval withdrawn for other than safety or effectiveness reasons, will be flagged in this Cumulative Supplement with the " ə " symbol to designate their non-marketed status. All products having a " ə " symbol in the 12th Cumulative Supplement of the 8th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 9th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 5, 1985 (50 FR 27688)
Tranylcypromine Sulfate	MAR 22, 1984 (49 FR 10708)

1.3 APPLICANT (NAME) CHANGES

Because it is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT (NAME) CHANGES

FORMER APPLICANT (NAME)	NEW APPLICANT (NAME)	NEW ABBREVIATED NAME
AYERST LABORATORIES INC DIV AMERICAN HOME PRODUCTS CORP	WYETH AYERST LABORATORIES INC	WYETH AYERST LABS
NOVOCOL CHEMICAL MANUFACTURING COMPANY INC	NOVOCOL PHARMACEUTICAL INC	NOVOCOL PHARM
WYETH INC	WYETH AYERST LABORATORIES INC	WYETH AYERST LABS
WYETH LABORATORIES INC	WYETH AYERST LABORATORIES INC	WYETH AYERST LABS
MY K LABORATORIES INC	PHARMACEUTICAL BASICS INC	PHARM BASICS

1.4 TRAZODONE HYDROCHLORIDE

Generic Trazodone HCl 150mg tablet entries, marked with a ( ), are rated as therapeutically equivalent (AB) to Mead Johnson's Desyrel (Trazodone HCl) Dividose 150mg tablets. The therapeutic equivalence determination, among other things, was made on the basis of an acceptable bioequivalence study and acceptable in vitro dissolution testing. A patent that exists on the Desyrel 150mg tablet scoring design, which enables the patient to break Desyrel into three 50mg segments, prevents a generic firm from copying this feature. Therefore, a patient will not be able to obtain three 50mg segments from the generic tablet. Prescribers and dispensers should be aware of this difference and take it into account when writing a prescription or practicing drug product selection.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1987) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product, provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

COUNTS CUMULATIVE BY QUARTER[1]

CATEGORIES COUNTED	DEC 1987	MAR 1988	JUN 1988	SEP 1988
DRUG PRODUCTS LISTED	9709	9528	9769	9993*
SINGLE SOURCE	2096 (21.6%)	1997 (21.0%)	1975 (20.2%)	1973 (19.7%)
MULTISOURCE	7613 (78.4%)	7531 (79.0%)	7794 (79.8%)	8020 (80.3%)
THERAPEUTICALLY EQUIVALENT	6691 (68.9%)	6660 (69.9%)	6937 (71.0%)	7161 (71.7)
NOT THERAPEUTICALLY EQUIVALENT	848 (8.7%)	770 (8.1%)	757 (7.8%)	749 (7.5)
EXCEPTIONS[2]	74 (0.8%)	101 (1.0)	100 (1.0%)	110 (1.1)
NEW MOLECULAR ENTITIES APPROVED	--	1	2	3
NUMBER OF APPLICANTS	349	361	378	387

*This number is inclusive of products discontinued since December 1987, and any products approved or discontinued through September 1988.

[1]Cumulative counts are calculated from January 1, 1988 to, and including, the month indicated.
[2]Amino acid-containing products of varying composition (see Introduction, page 1-8 of the List).

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

>ADD >	AB	HALSEY DRUG	325MG;50MG	N89568 001
>ADD >				OCT 05, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	MIKART	500MG;50MG;40MG	N89451 001
			MAY 23, 1988

BUTALBITAL, APAP, AND CAFFEINE

AB	HALSEY DRUG	325MG;50MG;40MG	N89536 001
			FEB 16, 1988

ACETAMINOPHEN; CODEINE PHOSPHATE

ELIXIR; ORAL

MYAPAP AND CODEINE

AA	MY K LABS	120MG/5ML;12MG/5ML	N87006 001

MYAPAP W/ CODEINE

/AA/	/MYK/LABS/	/120MG/5ML;12MG/5ML/	/N87006/001/

TYLENOL W/ CODEINE

/AA/	/MCNEIL/LABS/	/120MG/5ML;12MG/5ML/	/N85057/001/
AA	MCNEIL PHARM	120MG/5ML;12MG/5ML	N85057 001

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	BARR LABS	300MG;30MG	N85794 001
/AA/	/BOOTS/LABS/	/300MG;30MG/	/N87762/001/
			/DEC/10,/1982/
AA	CHARLOTTE PHARM	300MG;15MG	N89990 001
			SEP 30, 1988
AA		300MG;30MG	N89805 001
			SEP 30, 1988
AA		300MG;60MG	N89828 001
			SEP 30, 1988
AA	HALSEY DRUG	300MG;60MG	N86549 001
AA	MUTUAL PHARM	300MG;15MG	N89671 001
			FEB 10, 1988
AA		300MG;30MG	N89672 001
			FEB 10, 1988
AA		300MG;60MG	N89673 001
			FEB 10, 1988
AA	PHARMAFAIR	300MG;30MG	N87762 001
			DEC 10, 1982

ACETAMINOPHEN W/ CODEINE

/AA/	/BARR/LABS/	/300MG;30MG/	/N85794/001/

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN W/ CODEINE PHOSPHATE

/AA/	/HALSEY/DRUG/	/300MG;60MG/	/N86549/001/

TYLENOL W/ CODEINE

/AA/	/MCNEIL/LABS/	/325MG;7.5MG/	/N85056/001/
/AA/		/325MG;15MG/	/N85056/002/
/AA/		/325MG;30MG/	/N85056/003/
/AA/		/325MG;60MG/	/N85056/004/
AA	MCNEIL PHARM	325MG;7.5MG	N85056 001
AA		325MG;15MG	N85056 002
AA		325MG;30MG	N85056 003
AA		325MG;60MG	N85056 004

TYLENOL W/ CODEINE NO. 1

/AA/	/MCNEIL/LABS/	/300MG;7.5MG/	/N85055/001/
AA	MCNEIL PHARM	300MG;7.5MG	N85055 001

TYLENOL W/ CODEINE NO. 2

/AA/	/MCNEIL/LABS/	/300MG;15MG/	/N85055/002/
AA	MCNEIL PHARM	300MG;15MG	N85055 002

TYLENOL W/ CODEINE NO. 3

/AA/	/MCNEIL/LABS/	/300MG;30MG/	/N85055/003/
AA	MCNEIL PHARM	300MG;30MG	N85055 003

TYLENOL W/ CODEINE NO. 4

/AA/	/MCNEIL/LABS/	/300MG;60MG/	/N85055/004/
AA	MCNEIL PHARM	300MG;60MG	N85055 004

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

>ADD >	AA	GRAHAM LABS	500MG;5MG	N87336 001
>ADD >				JUL 08, 1982

CO-GESIC

AA	CENTRAL PHARMS	500MG;5MG	N89360 001
			MAR 02, 1988

LORCET-HD

>DLT >				
>DLT >/AA/	/GRAHAM/LABS/	/500MG;5MG/	/N87336/001/
>DLT >				/JUL/08,/1982/

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	BEECHAM LABS	650MG;7.5MG	N89725 001
			SEP 30, 1987
AA	CHARLOTTE PHARM	500MG;5MG	N89831 001
			SEP 07, 1988
AA	LUCHEM PHARMS	500MG;5MG	N89696 001
			APR 21, 1988
AA	MIKART	650MG;7.5MG	N89689 001
			JUN 29, 1988

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB	HALSEY DRUG	325MG;50MG	N72105 001 MAY 13, 1988
AB		650MG;100MG	N72106 001 MAY 13, 1988
AB	MYLAN PHARMS	650MG;100MG	N72195 001 FEB 16, 1988

ACETAZOLAMIDE

TABLET; ORAL
ACETAZOLAMIDE

AB	MUTUAL PHARM	125MG	N89752 001 JUN 22, 1988
AB		250MG	N89753 001 JUN 22, 1988

DIAMOX

AB	LEDERLE LABS	125MG	N08943 001

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION
ACETAZOLAMIDE SODIUM

AP	QUAD PHARMS	500MG/VIAL	N89619 001 JAN 13, 1988

DIAMOX

AP	LEDERLE LABS	500MG/VIAL	N09388 001

ACETOHYDROXAMIC ACID

TABLET; ORAL
LITHOSTAT

	MISSION PHARMA	250MG	N18749 001 MAY 31, 1983
	/URO/RES/	/250MG/	/N18749/001/ /MAY/31,/1983/

ALBUTEROL SULFATE

CAPSULE; INHALATION
VENTOLIN ROTACAPS

	GLAXO	EQ 0.2MG BASE	N19489 001 MAY 04, 1988

ALSEROXYLON

TABLET; ORAL
/RAUTENSIN/

/RP/	/DORSEY/LABS/	/2MG/	/N09215/001/
	∂ DORSEY LABS	2MG	N09215 001

/RAUNILOID/

/RP/	/RIKER/LABS/	/2MG/	/N08867/001/

RAUNILOID

	RIKER LABS	2MG	N08867 001

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
/AMANTADINE HCL/

/AB/	/REID/ROWELL/	/100MG/	/N71000/001/ /SEP/04,/1986/

SYMADINE

AB	REID ROWELL	100MG	N71000 001 SEP 04, 1986

AMCINONIDE

LOTION; TOPICAL
CYCLOCORT

	LEDERLE LABS	0.1%	N19729 001 JUN 13, 1988

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE

AB	BARR LABS	5MG;50MG	N71111 001 MAY 10, 1988

AMINO ACIDS

INJECTABLE; INJECTION
AMINOSYN 3.5% IN PLASTIC CONTAINER

>DLT>	/ABBOTT/LABS/	/3.5%/	/N18875/001/ /AUG/08,/1984/
>DLT>	∂ ABBOTT LABS	3.5%	N18875 001 AUG 08, 1984
>ADD>	/NEOPHAN/6.4%/		
>ADD>	/KABIVITRUM/	/6.4%/	/N18792/001/ /JAN/17,/1984/
	∂ KABIVITRUM	6.4%	N18792 001 JAN 17, 1984

TRAVASOL 10% IN PLASTIC CONTAINER

	BAXTER	10%	N18931 004 APR 27, 1988

AMINO ACIDS

INJECTABLE; INJECTION

>ADD> TROPHAMINE 10%
>ADD> KENDALL MCGAW 10%◊ N19018 003
>ADD> SEP 07, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
ABBOTT LABS 3.5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML 205MG/100ML◊ N19714 001
SEP 12, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
ABBOTT LABS 4.25%;36.8MG/100ML;20GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML 205MG/100ML◊ N19714 002
SEP 12, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
ABBOTT LABS 4.25%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML 205MG/100ML◊ N19714 004
SEP 12, 1988

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
ABBOTT LABS 5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML 205MG/100ML◊ N19714 003
SEP 12, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT LABS 3.5%;25GM/100ML◊ N19713 006
SEP 09, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT LABS 3.5%;5GM/100ML◊ N19713 002
SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
ABBOTT LABS 4.25%;10GM/100ML◊ N19713 001
SEP 09, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
ABBOTT LABS 4.25%;20GM/100ML◊ N19713 004
SEP 09, 1988

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT LABS 4.25%;25GM/100ML◊ N19713 005
SEP 09, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT LABS 5%;25GM/100ML◊ N19713 003
SEP 09, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER
ABBOTT LABS 4.25%;10GM/100ML;51MG/100ML; 176.5MG/100ML;22.4MG/100ML; 104.5MG/100ML; 205MG/100ML◊ N19712 002
SEP 08, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT LABS 3.5%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML◊ N19712 001
SEP 08, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES
KENDALL MCGAW 8.5%;110MG/100ML;230MG/100ML; 10MG/100ML;440MG/100ML; 690MG/100ML◊ N16822 007
JUL 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

>DLT>		AMINOSYN 3.5% N IN PLASTIC CONTAINER			
>DLT>		ABBOTT LABS	3.5%;21MG/100ML;40MG/100ML; 128MG/100ML; 234MG/100ML		N18875 002 AUG 08, 1984
>ADD>	ə	ABBOTT LABS	3.5%;21MG/100ML;40MG/100ML; 128MG/100ML; 234MG/100ML		N18875 002 AUG 08, 1984

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

AP	ABBOTT LABS	250MG/ML		N70888 001 JUN 16, 1988

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM

AP	MS&D	20%		N05619 001
AP	QUAD PHARMS	20%		N89821 001 JUL 14, 1988

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

BD	BARR LABS	100MG		N88297 001 AUG 19, 1983
BD		200MG		N88298 001 AUG 19, 1983
	ə BARR LABS	100MG		N88297 001 AUG 19, 1983
	ə	200MG		N88298 001 AUG 19, 1983
BD	HALSEY DRUG	100MG		N84674 001
BD	VALE CHEM	100MG		N84533 001

AMINOSALICYLATE SODIUM

TABLET; ORAL

BP	CNSOL MIDLAND	500MG		N07320 002
	ə CNSOL MIDLAND	500MG		N07320 002

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIL

AB	PARKE/DAVIS	10MG		N83939 001
AB		25MG		N83937 001
AB		50MG		N83938 002
AB		75MG		N84957 001
AB		100MG		N85093 001
AB		150MG		N86295 001

AMITRIPTYLINE HCL

>DLT> AB	LEDERLE LABS	10MG		N86744 001
>DLT> AB		25MG		N86746 001
>DLT> AB		50MG		N86743 001
>DLT> AB		75MG		N86745 001
>DLT> AB		100MG		N86747 001
>ADD>	ə LEDERLE LABS	10MG		N86744 001
>ADD>	ə	25MG		N86746 001
>ADD>	ə	50MG		N86743 001
>ADD>	ə	75MG		N86745 001
>ADD>	ə	100MG		N86747 001

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL

AB	PAR PHARM	EQ 12.5MG BASE;5MG		N72277 001 MAY 09, 1988
AB		25MG;10MG		N72278 001 MAY 09, 1988
AB	PHARM BASICS	EQ 12.5MG BASE;5MG		N70477 001 JAN 12, 1988
AB		EQ 25MG BASE;10MG		N70478 001 JAN 12, 1988

AMOXICILLIN

CAPSULE; ORAL

	AMOXICILLIN			
AB	CLONMEL CHEMS	250MG*	N62884 001	FEB 25, 1988
AB		500MG*	N62881 001	FEB 25, 1988

POWDER FOR RECONSTITUTION; ORAL

	POLYMOX			
AB	BRSTL MYRS IND	125MG/5ML*	N62885 001	MAR 08, 1988
AB		250MG/5ML*	N62885 002	MAR 08, 1988

AMPICILLIN SODIUM

INJECTABLE; INJECTION

		AMPICILLIN SODIUM			
> ADD >	AP	MARSAM PHARMS	EQ 125MG BASE/VIAL*	N62816 001	OCT 24, 1988
> ADD >	AP		EQ 250MG BASE/VIAL*	N62816 002	OCT 24, 1988
> ADD >	AP		EQ 500MG BASE/VIAL*	N62816 003	OCT 24, 1988
> ADD >	AP		EQ 1GM BASE/VIAL*	N62816 004	OCT 24, 1988
> ADD >	AP		EQ 2GM BASE/VIAL*	N62816 005	OCT 24, 1988
> ADD >	AP		EQ 10GM BASE/VIAL*	N62994 001	SEP 15, 1988

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

	AMPICILLIN			
AB	CLONMEL CHEMS	EQ 250MG BASE*	N62883 001	FEB 25, 1988
AB		EQ 500MG BASE*	N62882 001	FEB 25, 1988
AB	LEDERLE LABS	EQ 250MG BASE	N62208 001	
AB		EQ 500MG BASE	N62208 002	
	∂ LEDERLE LABS	EQ 250MG BASE	N62208 001	
	∂	EQ 500MG BASE	N62208 002	
	POLYCILLIN			
AB	BRSTL MYRS IND	EQ 250MG BASE*	N62888 001	MAR 04, 1988
AB		EQ 500MG BASE*	N62888 002	MAR 04, 1988

AMPICILLIN/AMPICILLIN TRIHYDRATE

POWDER FOR RECONSTITUTION; ORAL

> DLT >	AMPICILLIN			
> DLT > AB	AYERST LABS	EQ 125MG BASE/5ML	N50019 002	
> DLT > AB		EQ 250MG BASE/5ML	N50019 003	
> DLT > AB		EQ 100MG BASE/ML	N50019 001	
> ADD >	∂ AYERST LABS	EQ 125MG BASE/5ML	N50019 002	
> ADD >	∂	EQ 250MG BASE/5ML	N50019 003	
> ADD >	∂	EQ 100MG BASE/ML	N50019 001	

ANILERIDINE HYDROCHLORIDE

TABLET; ORAL

LERITINE			
NSAD	EQ 25MG BASE	N10585 002	
∂ MSD	EQ 25MG BASE	N10585 002	

ANILERIDINE PHOSPHATE

INJECTABLE; INJECTION

LERITINE			
MSD	EQ 25MG BASE/ML	N10520 003	
∂ MSD	EQ 25MG BASE/ML	N10520 003	

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

	ORPHENADRINE COMPOUND			
AB	VITARINE	385MG;30MG;25MG*	N71564 001	JUN 23, 1988
	ORPHENADRINE COMPOUND DOUBLE STRENGTH			
AB	VITARINE	770MG;60MG;50MG*	N71565 001	JUN 23, 1988

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

	COMPOUND 65			
AA	BANMAX PHARMS	389MG;32.4MG;65MG	N84553 002	AUG 17, 1983
	∂ BANMAX PHARMS	389MG;32.4MG;65MG	N84553 002	AUG 17, 1983

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

AZDONE

	CENTRAL PHARMS	500MG;5MG*	N89420 001 JAN 25, 1988

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	ICI PHARMS	50MG*	N72303 001 JUL 15, 1988
AB		100MG*	N72304 001 JUL 15, 1988

TENORMIN

AB	STUART PHARMS	50MG	N18240 001
AB		100MG	N18240 002

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

	CARNRICK LABS	0.025MG;1MG	N17744 002

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AZATHIOPRINE

AP	QUAD PHARMS	EQ 100MG BASE/VIAL*	N71056 001 JUN 08, 1988

IMURAN

AP	BURROUGHS WELLC	EQ 100MG BASE/VIAL	N17391 001

BACLOFEN

TABLET; ORAL

BACLOFEN

AB	PHARM BASICS	10MG*	N71260 001 MAY 06, 1988
AB		20MG*	N71261 001 MAY 06, 1988
AB	VITARINE	10MG*	N71901 001 APR 13, 1988
AB		20MG*	N71902 001 APR 13, 1988

BACLOFEN

TABLET; ORAL

BACLOFEN

AB	ZENITH LABS	10MG*	N72234 001 JUL 21, 1988
AB		20MG*	N72235 001 JUL 21, 1988

LIORESAL

AB	GEIGY PHARMS	10MG	N17851 001

LIORESAL DS

AB	GEIGY PHARMS	20MG	N17851 003 JAN 20, 1982

BENZTHIAZIDE

TABLET; ORAL

BENZTHIAZIDE

	∂ PRIVATE FMLTNS	50MG	N83206 001

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA	PAR PHARM	0.5MG	N88877 001 APR 11, 1985
AA		1MG	N88894 001 APR 11, 1985
AA		2MG	N88895 001 APR 11, 1985

AA	PHARM BASICS	0.5MG*	N89211 001 JUN 14, 1988
AA		1MG*	N89212 001 JUN 14, 1988
AA		2MG*	N89213 001 JUN 14, 1988

BENZTROPINE MESYLATE

TABLET; ORAL

	BENZTROPINE MESYLATE			
AA	QUANTUM PHARMCS	0.5MG	N88514 001	JAN 31, 1984
AA		1MG	N88510 001	JAN 31, 1984
AA		2MG	N88511 001	JAN 31, 1984
/BP/		/0.5MG/	/N88514/001/	/JAN/31,/1984/
/BP/		/1MG/	/N88510/001/	/JAN/31,/1984/
/BP/		/2MG/	/N88511/001/	/JAN/31,/1984/
AA	SIDMAK LABS	0.5MG◊	N89058 001	AUG 10, 1988
AA		1MG◊	N89059 001	AUG 10, 1988
AA		2MG◊	N89060 001	AUG 10, 1988
	COGENTIN			
AA	MS&D	0.5MG	N09193 004	
AA		1MG	N09193 003	
AA		2MG	N09193 002	
/BP/		/0.5MG/	/N09193/004/	
/BP/		/1MG/	/N09193/003/	
/BP/		/2MG/	/N09193/002/	

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

	BETAMETHASONE DIPROPIONATE			
AB	COPLEY PHARM	EQ 0.05% BASE◊	N71882 001	JUN 06, 1988
AB	THAMES PHARMA	EQ 0.05% BASE◊	N72276 001	AUG 24, 1988
	DIPROLENE			
BX	SCHERING	EQ 0.05% BASE◊	N19716 001	AUG 01, 1988

BETAMETHASONE VALERATE

CREAM; TOPICAL

	DERMABET			
AB	TARO PHARMS	EQ 0.1% BASE◊	N72041 001	JAN 06, 1988

BETAMETHASONE VALERATE

LOTION; TOPICAL

	BETAMETHASONE VALERATE			
AB	COPLEY PHARM	EQ 0.1% BASE◊	N71883 001	APR 22, 1988

BETAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

	/HISTALOG/			
	/LILLY/	/50MG/ML/	/N09344/001/	
	ə LILLY	50MG/ML	N09344 001	

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

	BETHANECHOL CHLORIDE			
AP	QUAD PHARMS	5MG/ML◊	N89815 001	APR 12, 1988
	URECHOLINE			
AP	MS&D	5MG/ML	N06536 001	

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

	BRETYLIUM TOSYLATE			
AP	LUITPOLD PHARMS	50MG/ML◊	N70891 001	JUL 26, 1988
AP	QUAD PHARMS	50MG/ML◊	N71181 001	FEB 16, 1988

BROMPHENIRAMINE MALEATE

TABLET; ORAL

	BROMPHENIRAMINE MALEATE			
/AA/	/BARR/LABS/	/4MG/	/N84468/001/	
	ə BARR LABS	4MG	N84468 001	

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HCL AND EPINEPHRINE

ABBOTT LABS	0.25%;0.005MG/ML¤	N71165 001	JUN 16, 1988
	0.25%;0.005MG/ML¤	N71166 001	JUN 16, 1988
	0.25%;0.005MG/ML¤	N71167 001	JUN 16, 1988
	0.5%;0.005MG/ML¤	N71168 001	JUN 16, 1988
	0.5%;0.005MG/ML¤	N71169 001	JUN 16, 1988
	0.5%;0.005MG/ML¤	N71170 001	JUN 16, 1988
	0.75%;0.005MG/ML¤	N71171 001	JUN 16, 1988

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	BAXTER	25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML¤	N17512 010	NOV 18, 1985	> ADD >

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	BAXTER	25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤	N17512 011	NOV 18, 1985	> ADD >

INPERSOL W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	ABBOTT LABS	25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML¤	N18379 007	JUN 24, 1988	> ADD >

INPERSOL-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	ABBOTT LABS	25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML¤	N18379 008	JUN 24, 1988	> ADD >

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

KENDALL MCGAW	10MG/100ML;2.5GM/100ML;15MG/100ML; 300MG/100ML; 160MG/100ML¤	N19634 001	FEB 24, 1988

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

KENDALL MCGAW	4MG/100ML;4GM/100ML;6MG/100ML; 120MG/100ML;62MG/100ML¤	N19634 002	FEB 24, 1988

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP	KENDALL MCGAW	20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML; 310MG/100ML¤	N19634 003	FEB 24, 1988	> ADD >

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT LABS	20MG/100ML;5GM/100ML;104MG/100ML; 600MG/100ML; 310MG/100ML¤	N19685 005	OCT 17, 1988	> ADD >
AP		20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML; 310MG/ML¤	N19685 006	OCT 17, 1988	> ADD >

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT LABS	20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML; 310MG/100ML¤	N19685 007	OCT 17, 1988	> ADD >

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT LABS	20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML; 310MG/100ML¤	N19685 002	OCT 17, 1988	> ADD >
AP		20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML; 310MG/100ML¤	N19685 008	OCT 17, 1988	> ADD >

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT LABS	20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML; 310MG/100ML¤	N19685 003	OCT 17, 1988	> ADD >

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

> ADD >	AP	ABBOTT LABS	20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML; 310MG/100ML¤	N19685 004 OCT 17, 1988	

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

> ADD >	AP	ABBOTT LABS	20MG/100ML;5GM/100ML;104MG/100ML; 600MG/100ML; 310MG/100ML¤	N19685 001 OCT 17, 1988	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	KENDALL MCGAW	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML¤	N19632 001 FEB 29, 1988	

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

AB	NARNER CHILCOTT	100MG¤	N71940 001 FEB 01, 1988	

TEGRETOL

AB	GEIGY PHARMS	100MG	N18281 001	

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

> ADD >	AA	PIONEER PHARMS	350MG¤	N89390 001 OCT 13, 1988	
> ADD >	AA	VITARINE	350MG¤	N89566 001 AUG 30, 1988	

CARPHENAZINE MALEATE

> DLT >		/TABLET;ORAL/			
> DLT >		/PROKETAZINE/			
> DLT >		/WYETH/AYERST/LABS/	/25MG/		/N12768/002/
> ADD >		@ WYETH AYERST LABS	25MG	N12768 002	
> DLT >			/50MG/		/N12768/004/
> ADD >		@	50MG	N12768 004	

CEFACLOR

POWDER FOR RECONSTITUTION; ORAL

CECLOR

	LILLY	EQ 187MG BASE/5ML¤	N62206 003 APR 20, 1988	
		EQ 375MG BASE/5ML¤	N62206 004 APR 20, 1988	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF

AP	SK&F LABS	EQ 5GM BASE/VIAL	N50461 004	

CEFAZOLIN SODIUM

AP	BEN VENUE LABS	EQ 250MG BASE/VIAL¤	N62894 001 JUL 21, 1988	
AP		EQ 500MG BASE/VIAL¤	N62894 002 JUL 21, 1988	
AP		EQ 1GM BASE/VIAL¤	N62894 003 JUL 21, 1988	
AP		EQ 5GM BASE/VIAL¤	N62894 004 JUL 21, 1988	
AP		EQ 10GM BASE/VIAL¤	N62894 005 JUL 21, 1988	
AP	ELKINS SINN	EQ 250MG BASE/VIAL¤	N62807 001 JAN 12, 1988	
AP		EQ 500MG BASE/VIAL¤	N62807 002 JAN 12, 1988	
AP		EQ 1GM BASE/VIAL¤	N62807 003 JAN 12, 1988	
AP		EQ 5GM BASE/VIAL¤	N62807 004 JAN 12, 1988	
AP		EQ 10GM BASE/VIAL¤	N62807 005 JAN 12, 1988	
AP		EQ 20GM BASE/VIAL¤	N62807 006 JAN 12, 1988	

CEFOTETAN DISODIUM

INJECTABLE; INJECTION
CEFOTAN

	STUART PHARMS	EQ 10GM BASE/VIAL‡	N50588 003 APR 25, 1988

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

AB	JEROME STEVENS	EQ 250MG BASE‡	N62870 001 MAR 17, 1988
AB		EQ 500MG BASE‡	N62869 001 MAR 17, 1988
AB	LABROS ATRAL	EQ 250MG BASE‡	N62713 001 JUL 15, 1988
AB		EQ 500MG BASE‡	N62713 002 JUL 15, 1988
AB	TAG PHARMS	EQ 250MG BASE‡	N62821 001 FEB 05, 1988
AB		EQ 500MG BASE‡	N62823 001 FEB 05, 1988
AB	YOSHITOMI PHARM	EQ 250MG BASE‡	N62872 001 JUN 20, 1988
AB		EQ 500MG BASE‡	N62871 001 JUL 05, 1988

POWDER FOR RECONSTITUTION; ORAL
CEPHALEXIN

AB	TAG PHARMS	EQ 125MG BASE/5ML‡	N62873 001 MAY 23, 1988
AB		EQ 250MG BASE/5ML‡	N62867 001 APR 15, 1988

TABLET; ORAL
CEPHALEXIN

AB	VITARINE	EQ 250MG BASE‡	N62863 001 AUG 11, 1988
AB		EQ 500MG BASE‡	N62863 002 AUG 11, 1988
AB		EQ 1GM BASE‡	N62863 003 AUG 11, 1988

KEFLET

AB	LILLY	EQ 1GM BASE	N50440 002

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL
KEFTAB

	LILLY	EQ 333MG BASE‡	N50614 003 MAY 16, 1988

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION
CEFADYL

AP	BRSTL MYRS IND	EQ 500MG BASE/VIAL‡	N62961 001 SEP 20, 1988
AP		EQ 1GM BASE/VIAL‡	N62961 002 SEP 20, 1988
AP		EQ 2GM BASE/VIAL‡	N62961 003 SEP 20, 1988
AP		EQ 4GM BASE/VIAL‡	N62961 004 SEP 20, 1988

CEPHRADINE

CAPSULE; ORAL
CEPHRADINE

AB	BARR LABS	250MG‡	N62850 001 APR 22, 1988
AB		500MG‡	N62851 001 APR 22, 1988
AB	VITARINE	250MG‡	N62813 001 FEB 25, 1988
AB		500MG‡	N62813 002 FEB 25, 1988

POWDER FOR RECONSTITUTION; ORAL
CEPHRADINE

AB	BARR LABS	125MG/5ML‡	N62858 001 MAY 19, 1988
AB		250MG/5ML‡	N62859 001 MAY 19, 1988

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL

>DLT>/AB/	/LEDERLE LABS/	/5MG/	/N86892/001/
>DLT>/AB/		/10MG/	/N86876/001/
>DLT>/AB/		/25MG/	/N86893/001/
>ADD>	∂ LEDERLE LABS	5MG	N86892 001
>ADD>	∂	10MG	N86876 001
>ADD>	∂	25MG	N86893 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL

AB	PIONEER PHARMS	10MG	N89533 001
			JUL 15, 1988
AB		25MG	N89558 001
			JUL 15, 1988
/AB/	/PUREPAC/PHARM/	/5MG/	/N85155/001/
/AB/		/10MG/	/N84939/002/
/AB/		/25MG/	/N85144/001/
	ə PUREPAC PHARM	5MG	N85155 001
	ə	10MG	N84939 002
	ə	25MG	N85144 001
	/LYGEN/		
/AB/	/BANMAX/PHARMS/	/5MG/	/N85107/002/
/AB/		/10MG/	/N85009/001/
/AB/		/25MG/	/N85108/001/
	ə BANMAX PHARMS	5MG	N85107 002
	ə	10MG	N85009 001
	ə	25MG	N85108 001

CHLORMERODRIN, HG-197

>DLT>	/INJECTABLE;/INJECTION/		
>DLT>	/CHLORMERODRIN/HG/197/		
>DLT>	/SQUIBB/	/0.6-1.4MCI/ML/	/N17269/001/
>ADD>	ə SQUIBB	0.6-1.4MCI/ML	N17269 001

CHLOROQUINE PHOSPHATE

>DLT>	/INJECTABLE;/INJECTION/		
>DLT>	/ARALEN/		
>DLT>	/STERLING/DRUG/	/EQ/40MG/BASE/ML/	/N06002/002/
>ADD>	ə STERLING DRUG	EQ 40MG BASE/ML	N06002 002

TABLET; ORAL

ARALEN

AA	STERLING DRUG	EQ 300MG BASE	N06002 001

CHLOROQUINE PHOSPHATE

AA	DANBURY PHARMA	EQ 300MG BASE	N88030 001
			DEC 21, 1982
/AA/		/EQ 300MG BASE/	/N88030/001/
			/DEC/21/1982/

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

>DLT>	/TABLET;/ORAL/		
>DLT>	/ARALEN/PHOSPHATE/W//PRIMAQUINE/PHOSPHATE/		
>DLT>	/STERLING/DRUG/	/EQ/300MG/BASE;/	
>DLT>		/EQ/45MG/BASE/	/N14860/002/
>ADD>	ə STERLING DRUG	EQ 300MG BASE;	
>ADD>		EQ 45MG BASE	N14860 002

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

>DLT>	/AA/	/LEDERLE/LABS/	/250MG/	/N86940/001/
>DLT>	/AA/		/500MG/	/N86938/001/
>ADD>		ə LEDERLE LABS	250MG	N86940 001
>ADD>		ə	500MG	N86938 001

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CHLOROTHIAZIDE W/ RESERPINE

/BP/	/BOLAR/PHARM/	/250MG;0.125MG/	/N84853/001/
	ə BOLAR PHARM	250MG;0.125MG	N84853 001

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

CHLORPHENIRAMINE MALEATE

/AA/	/BARR/LABS/	/4MG/	/N80700/001/
	ə BARR LABS	4MG	N80700 001

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HCL

AP	MARSAM PHARMS	25MG/ML	N89563 001
			APR 15, 1988

TABLET; ORAL

CHLORPROMAZINE HCL

>DLT>	/BP/	/LEDERLE/LABS/	/25MG/	/N84801/001/
>DLT>	/BP/		/50MG/	/N84800/001/
>DLT>	/BP/		/200MG/	/N84802/001/
>ADD>		ə LEDERLE LABS	25MG	N84801 001
>ADD>		ə	50MG	N84800 001
>ADD>		ə	200MG	N84802 001

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB	MUTUAL PHARM	25MG	N89738 001 SEP 19, 1988	
AB		50MG	N89739 001 SEP 19, 1988	
AB	PIONEER PHARMS	50MG	N89591 001 JUL 21, 1988	>ADD> >ADD>

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AA	BARR LABS	500MG	N89895 001 MAY 04, 1988
AA	CORD LABS	250MG	N89852 001 MAY 04, 1988
AA		500MG	N89853 001 MAY 04, 1988
AA	LEMMON	500MG	N89859 001 MAY 04, 1988

PARAFON FORTE DSC

AA	MCNEIL PHARM	500MG	N11529 002 JUN 15, 1987

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL

CHOLYBAR

PARKE DAVIS	EQ 4GM RESIN/BAR	N71621 001 MAY 26, 1988
	EQ 4GM RESIN/BAR	N71739 001 MAY 26, 1988

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN

AB	UPJOHN MFG	EQ 75MG BASE	N61809 001
AB		EQ 150MG BASE	N61809 002

CLEOCIN HCL

UPJOHN	EQ 300MG BASE	N50162 003 APR 14, 1988

CLINDAMYCIN HCL

AB	VITARINE	EQ 75MG BASE	N62910 001 JUL 05, 1988
AB		EQ 150MG BASE	N62910 002 JUL 05, 1988

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP	ABBOTT LABS	EQ 150MG BASE/ML	N62943 001 SEP 29, 1988
AP	LOCH PHARMS	EQ 150MG BASE/ML	N62905 001 MAY 09, 1988
AP	MARSAM PHARMS	EQ 150MG BASE/ML	N62913 001 OCT 20, 1988
AP	ELKINS SINN	EQ 150MG BASE/ML	N62953 001 APR 21, 1988
AP	LEDERLE PARNTLS	EQ 150MG BASE/ML	N62889 001 APR 25, 1988
AP	LEMMON	EQ 150MG BASE/ML	N62900 001 JUN 08, 1988
AP	LYPHOMED	EQ 150MG BASE/ML	N62747 001 JUN 03, 1988
AP	QUAD PHARMS	EQ 150MG BASE/ML	N62877 001 MAR 15, 1988
AP	SOLOPAK LABS	EQ 150MG BASE/ML	N62819 001 MAR 15, 1988
AP		EQ 150MG BASE/ML	N62852 001 MAR 17, 1988

SOLUTION; TOPICAL

CLEOCIN T

AT	UPJOHN	EQ 1% BASE	N50537 001
AT		EQ 1% BASE	N62363 001 FEB 08, 1982

CLINDAMYCIN PHOSPHATE

AT	BARRE NATL	EQ 1% BASE	N62811 001 SEP 01, 1988

CLOFIBRATE

CAPSULE; ORAL

CLOFIBRATE

AB	CORD LABS	500MG	N72191 001 MAY 02, 1988

CLOMIPHENE CITRATE

TABLET; ORAL

/CLOMIPHENE CITRATE/

/AB/	/PLANTEX/	/50MG/		/N18361/001/ MAR/22/1982/

12

CLOMIPHENE CITRATE

TABLET; ORAL
SEROPHENE

AB	SERONO LABS	50MG	N18361 001 MAR 22, 1982

CLONIDINE

FILM, CONTROLLED RELEASE; PERCUTANEOUS
CATAPRES-TTS-1

	BOEHR INGEL	0.1MG/24HR	N18891 001 OCT 10, 1984
		/2.5MG/	/N18891/001/ /Oct/10./1984/

CATAPRES-TTS-2

	BOEHR INGEL	0.2MG/24HR	N18891 002 OCT 10, 1984
		/5MG/	/N18891/002/ /Oct/10./1984/

CATAPRES-TTS-3

	BOEHR INGEL	0.3MG/24HR	N18891 003 OCT 10, 1984
		/7.5MG/	/N18891/003/ /Oct/10./1984/

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL

AB	CORD LABS	0.1MG*	N70887 001 AUG 31, 1988
AB		0.2MG*	N70886 001 AUG 31, 1988
AB		0.3MG*	N71294 001 AUG 31, 1988
AB	LEDERLE LABS	0.1MG*	N71783 001 APR 05, 1988
AB		0.2MG*	N71784 001 APR 05, 1988
AB		0.3MG*	N71785 001 APR 05, 1988
AB	WARNER CHILCOTT	0.1MG*	N72138 001 JUN 13, 1988
AB		0.2MG*	N72139 001 JUN 13, 1988
AB		0.3MG*	N72140 001 JUN 13, 1988

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

AB	CHELSEA LABS	3.75MG*	N71878 001 MAR 15, 1988
AB		7.5MG*	N71879 001 MAR 15, 1988
AB		15MG*	N71860 001 MAR 15, 1988
AB	CORD LABS	3.75MG*	N72219 001 AUG 26, 1988
AB		7.5MG*	N72220 001 AUG 26, 1988
AB		15MG*	N72112 001 AUG 26, 1988
AB	PUREPAC PHARM	3.75MG*	N71924 001 APR 25, 1988
AB		7.5MG*	N71925 001 APR 25, 1988
AB		15MG*	N71926 001 APR 25, 1988
AB	QUANTUM PHARMCS	3.75MG*	N71549 001 SEP 12, 1988
AB		7.5MG*	N71550 001 SEP 12, 1988
AB		15MG*	N71522 001 SEP 12, 1988
AB	WARNER CHILCOTT	3.75MG*	N71774 001 MAR 01, 1988
AB		7.5MG*	N71775 001 MAR 01, 1988
AB		15MG*	N71776 001 MAR 01, 1988

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM

AB	PUREPAC PHARM	3.75MG*	N72330 001 AUG 08, 1988
AB		7.5MG*	N72331 001 AUG 08, 1988
AB		15MG*	N72332 001 AUG 08, 1988
AB	WARNER CHILCOTT	3.75MG*	N71828 001 MAR 03, 1988
AB		7.5MG*	N71829 001 MAR 03, 1988
AB		15MG*	N71830 001 MAR 03, 1988

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

	CLORAZEPATE DIPOTASSIUM			
AB	WATSON LABS	3.75MG*	N71852 001	FEB 09, 1988
AB		7.5MG*	N71853 001	FEB 09, 1988
AB		15MG*	N71854 001	FEB 09, 1988
	GEN-XENE			
AB	ALRA LABS	3.75MG*	N71787 001	APR 26, 1988
AB		7.5MG*	N71788 001	APR 26, 1988
AB		15MG*	N71789 001	APR 26, 1988

CLOXACILLIN SODIUM

POWDER FOR RECONSTITUTION; ORAL

	CLOXACILLIN SODIUM			
AA	BIOCRAFT LABS	EQ 125MG BASE/5ML	N62268 001	
/AB/		/EQ 125MG BASE/5ML/	/N62268/001/	
	TEGOPEN			
AA	BRISTOL LABS	EQ 125MG BASE/5ML	N50192 001	
AA		EQ 125MG BASE/5ML	N61453 001	
/AB/		/EQ 125MG BASE/5ML/	/N50192/001/	
/AB/		/EQ 125MG BASE/5ML/	/N61453/001/	

COLCHICINE; PROBENECID

TABLET; ORAL

	PROBENECID AND COLCHICINE			
/BP/	/BEECHAM LABS/	/0.5MG;500MG/	/N84321/001/	
	∂ BEECHAM LABS	0.5MG;500MG	N84321 001	
	PROBENECID W/ COLCHICINE			
/BP/	/LEDERLE LABS/	/0.5MG;500MG/	/N86954/001/	
	∂ LEDERLE LABS	0.5MG;500MG	N86954 001	

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

	INTRAUTERINE COPPER CONTRACEPTIVE			
	POP COUNCIL CBR	APPROX 176MG COPPER*	N18680 002	APR 29, 1988

CYCLACILLIN

TABLET; ORAL

	CYCLACILLIN			
AB	BIOCRAFT LABS	250MG*	N62895 001	AUG 04, 1988
AB		500MG*	N62895 002	AUG 04, 1988
	CYCLAPEN-N			
AB	WYETH AYERST LABS	250MG	N50509 001	
AB		500MG	N50509 002	

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

	CYCLOBENZAPRINE HCL			
AB	DANBURY PHARMA	10MG*	N71611 001	MAY 03, 1989 : FEB 29, 1988
	FLEXERIL			
AB	MSD	10MG	N17821 002	

CYCRIMINE HYDROCHLORIDE

> DLT >	/TABLET;ORAL/				
> DLT >	/PAGITANE/				
> DLT >	/LILLY/	/1.25MG/	/N08951/001/		
> ADD >	∂ LILLY	1.25MG	N08951 001		
> DLT >		/2.5MG/	/N08951/002/		
> ADD >	∂	2.5MG	N08951 002		

CYTARABINE

INJECTABLE; INJECTION

CYTOSAR-U			
UPJOHN	1GM/VIAL	N16793 003	DEC 21, 1987
	2GM/VIAL	N16793 004	DEC 21, 1987

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE			
QUAD PHARMS	500MG/VIAL*	N71563 001	MAY 06, 1988

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HCL

AB	CORD LABS	10MG	N72099 001 MAY 24, 1988
AB		25MG	N72100 001 MAY 24, 1988
AB		50MG	N72101 001 MAY 24, 1988
AB		75MG	N72102 001 JUN 20, 1988
AB		100MG	N72103 001 JUN 20, 1988
AB		150MG	N72104 001 JUN 20, 1988
AB	VITARINE	10MG	N72167 001 FEB 03, 1988
AB		150MG	N72254 001 FEB 03, 1988

NORPRAMIN

AB	MERRELL DON	10MG	N14399 007 FEB 11, 1982
AB		150MG	N14399 006

DESONIDE

OINTMENT; TOPICAL

DESONEN

AB	OWEN LABS	0.05%	N71425 001 JUN 15, 1988

TRIDESILON

AB	MILES PHARM	0.05%	N17426 001

DESOXYCORTICOSTERONE ACETATE

PELLET; IMPLANTATION

/PERCORTEN/

/CIBA/PHARM/	/125MG/	/N05151/001/
ə CIBA PHARM	125MG	N05151 001

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

/BP/	/BARR/LABS/	/0.25MG/	/N84013/001/
/BP/		/0.25MG/	/N84764/001/
/BP/		/0.5MG/	/N84084/001/
/BP/		/0.75MG/	/N84081/001/
/BP/		/0.75MG/	/N84765/001/
/BP/		/1.5MG/	/N84086/001/
/BP/		/1.5MG/	/N84763/001/
	ə BARR LABS	0.25MG	N84013 001
	ə	0.25MG	N84764 001
	ə	0.5MG	N84084 001
	ə	0.75MG	N84081 001
	ə	0.75MG	N84765 001
	ə	1.5MG	N84086 001
	ə	1.5MG	N84763 001

DEXAMETHASONE; TOBRAMYCIN

OINTMENT; OPHTHALMIC

TOBRADEX

ALCON LABS	0.1%;0.3%	N50616 001 SEP 28, 1988

SUSPENSION/DROPS; OPHTHALMIC

TOBRADEX

ALCON LABS	0.1%;0.3%	N50592 001 AUG 18, 1988

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

/PHENERGAN W/ DEXTROMETHORPHAN/

/AA/	/WYETH/AYERST/LABS/	/15MG/5ML;6.25MG/5ML/	/N11265/002/ /APR/02/1984/

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	10GM/100ML	N19626 004 FEB 02, 1988

DEXTROSE 2.5% IN PLASTIC CONTAINER

KENDALL MCGAW	2.5GM/100ML	N19626 001 FEB 02, 1988

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 5% IN PLASTIC CONTAINER

>ADD>	AP	ABBOTT LABS	50MG/ML	N19222 001 JUL 13, 1984
>ADD>		/$/	/50MG/ML/	/N19222/001/ /JUL/13,/1984/
>DLT>				
>DLT>				
	AP	KENDALL MCGAN	5GM/100ML	N19626 002 FEB 02, 1988

DEXTROSE 7.7% IN PLASTIC CONTAINER

	KENDALL MCGAN	7.7GM/100ML	N19626 003 FEB 02, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

/DEXTROSE/5%/AND/SODIUM/CHLORIDE/0.3%/W//POTASSIUM/CHLORIDE/ /0.075%/IN/PLASTIC/CONTAINER/

	/ABBOTT/LABS/	/5GM/100ML;74.5MG/100ML;/ 300MG/100ML/	/N18876/001/ /JAN/17,/1986/

/DEXTROSE/5%/AND/SODIUM/CHLORIDE/0.3%/W//POTASSIUM/CHLORIDE/ /0.15%/IN/PLASTIC/CONTAINER/

	/ABBOTT/LABS/	/5GM/100ML;149MG/100ML;/ 300MG/100ML/	/N18876/002/ /JAN/17,/1986/

/DEXTROSE/5%/AND/SODIUM/CHLORIDE/0.3%/W//POTASSIUM/CHLORIDE/ /0.224%/IN/PLASTIC/CONTAINER/

	/ABBOTT/LABS/	/5GM/100ML;224MG/100ML;/ 300MG/100ML/	/N18876/003/ /JAN/17,/1986/

/DEXTROSE/5%/SODIUM/CHLORIDE/0.225%/POTASSIUM/CHLORIDE/ /0.15%/IN/PLASTIC/CONTAINER/

	/ABBOTT/LABS/	/5GM/100ML;150MG/100ML;/ 225MG/100ML/	/N18365/001/

/DEXTROSE 5%; SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE/ /0.075% IN PLASTIC CONTAINER/

/AP/	/ABBOTT/LABS/	/5GM/100ML;224MG/100ML;/ 450MG/100ML/	/N18362/002/

/DEXTROSE 5%; SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE/ /0.3% IN PLASTIC CONTAINER/

/AP/	/ABBOTT/LABS/	/5GM/100ML;298MG/100ML;/ 450MG/100ML/	/N18362/003/

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	KENDALL MCGAN	10GM/100ML;37MG/100ML; 200MG/100ML	N19630 031 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	KENDALL MCGAN	10GM/100ML;37MG/100ML; 450MG/100ML	N19630 037 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	KENDALL MCGAN	10GM/100ML;37MG/100ML; 900MG/100ML	N19630 043 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	KENDALL MCGAN	5GM/100ML;37MG/100ML; 110MG/100ML	N19630 001 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	KENDALL MCGAN	5GM/100ML;37MG/100ML; 200MG/100ML	N19630 007 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

	KENDALL MCGAN	5GM/100ML;37MG/100ML; 330MG/100ML	N19630 013 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	KENDALL MCGAN	5GM/100ML;37MG/100ML; 450MG/100ML	N19630 019 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	KENDALL MCGAN	5GM/100ML;37MG/100ML; 900MG/100ML	N19630 025 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	KENDALL MCGAN	10GM/100ML;75MG/100ML; 200MG/100ML	N19630 032 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	KENDALL MCGAN	10GM/100ML;75MG/100ML; 450MG/100ML	N19630 038 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	KENDALL MCGAN	10GM/100ML;75MG/100ML; 900MG/100ML	N19630 044 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;75MG/100ML; 200MG/100ML‡ N19630 008 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;75MG/100ML; 330MG/100ML‡ N19630 014 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;75MG/100ML; 450MG/100ML‡ N19630 020 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;75MG/100ML; 900MG/100ML‡ N19630 026 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

KENDALL MCGAW 5GM/100ML;75MG/100ML; 110MG/100ML‡ N19630 002 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

KENDALL MCGAW 10GM/100ML;110MG/100ML; 200MG/100ML‡ N19630 033 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

KENDALL MCGAW 10GM/100ML;110MG/100ML; 450MG/100ML‡ N19630 039 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

KENDALL MCGAW 10GM/100ML;110MG/100ML; 900MG/100ML‡ N19630 045 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

KENDALL MCGAW 5GM/100ML;110MG/100ML; 110MG/100ML‡ N19630 003 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

KENDALL MCGAW 5GM/100ML;110MG/100ML; 200MG/100ML‡ N19630 009 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

KENDALL MCGAW 5GM/100ML;110MG/100ML; 330MG/100ML‡ N19630 015 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

KENDALL MCGAW 5GM/100ML;110MG/100ML; 450MG/100ML‡ N19630 021 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

KENDALL MCGAW 5GM/100ML;110MG/100ML; 900MG/100ML‡ N19630 027 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

KENDALL MCGAW 10GM/100ML;150MG/100ML; 200MG/100ML‡ N19630 034 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

KENDALL MCGAW 10GM/100ML;150MG/100ML; 450MG/100ML‡ N19630 040 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

KENDALL MCGAW 10GM/100ML;150MG/100ML; 900MG/100ML‡ N19630 046 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;150MG/100ML; 200MG/100ML‡ N19630 010 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;150MG/100ML; 330MG/100ML‡ N19630 016 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;150MG/100ML; 450MG/100ML‡ N19630 022 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;150MG/100ML; 900MG/100MLM N19630 028 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;150MG/100ML; 110MG/100MLM N19630 004 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;220MG/100ML; 200MG/100MLM N19630 035 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;220MG/100ML; 450MG/100MLM N19630 041 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;220MG/100ML; 900MG/100MLM N19630 047 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;220MG/100ML; 110MG/100MLM N19630 005 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;220MG/100ML; 200MG/100MLM N19630 011 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;220MG/100ML; 330MG/100MLM N19630 017 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;220MG/100ML; 450MG/100MLM N19630 023 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;220MG/100ML; 900MG/100MLM N19630 029 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;300MG/100ML; 200MG/100MLM N19630 036 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;300MG/100ML; 450MG/100MLM N19630 042 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;300MG/100ML; 900MG/100MLM N19630 048 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;300MG/100ML; 200MG/100MLM N19630 012 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;300MG/100ML; 330MG/100MLM N19630 018 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;300MG/100ML; 450MG/100MLM N19630 024 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP KENDALL MCGAW 5GM/100ML;300MG/100ML; 900MG/100MLM N19630 030 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAW 5GM/100ML;300MG/100ML; 110MG/100MLM N19630 006 FEB 17, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP ABBOTT LABS 5GM/100ML;74.5MG/100ML; 450MG/100MLM N18362 009 JUL 05, 1983

AP 5GM/100ML;149MG/100ML; 450MG/100MLM N18362 005 MAR 28, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT LABS	5GM/100ML;74.5MG/100ML; 900MG/100ML‡	N19691 002 MAR 24, 1988
AP		5GM/100ML;149MG/100ML; 900MG/100ML‡	N19691 004 MAR 24, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT LABS	5GM/100ML;74.5MG/100ML; 225MG/100ML‡	N18365 002 JUL 05, 1983
		5GM/100ML;149MG/100ML; 225MG/100ML‡	N18365 006 MAR 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT LABS	5GM/100ML;74.5MG/100ML; 300MG/100ML	N18876 001 JAN 17, 1986
		5GM/100ML;149MG/100ML; 300MG/100ML‡	N18876 006 MAR 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	TRAVENOL LABS	5GM/100ML;75MG/100ML; 900MG/100ML‡	N19308 004 APR 05, 1985

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT LABS	5GM/100ML;224MG/100ML; 450MG/100ML‡	N18362 006 MAR 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT LABS	5GM/100ML;224MG/100ML; 900MG/100ML‡	N19691 006 MAR 24, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT LABS	5GM/100ML;224MG/100ML; 225MG/100ML‡	N18365 008 MAR 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT LABS	5GM/100ML;224MG/100ML; 300MG/100ML‡	N18876 007 MAR 28, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT LABS	5GM/100ML;149MG/100ML; 450MG/100ML‡	N18362 010 JUL 05, 1983
AP		5GM/100ML;298MG/100ML; 450MG/100ML‡	N18362 007 MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT LABS	5GM/100ML;149MG/100ML; 900MG/100ML‡	N19691 005 MAR 24, 1988
AP		5GM/100ML;298MG/100ML; 900MG/100ML‡	N19691 008 MAR 24, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT LABS	5GM/100ML;149MG/100ML; 225MG/100ML	N18365 001
		5GM/100ML;298MG/100ML; 225MG/100ML‡	N18365 009 MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT LABS	5GM/100ML;298MG/100ML; 300MG/100ML‡	N18876 008 MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT LABS	5GM/100ML;149MG/100ML; 300MG/100ML	N18876 002 JAN 17, 1986

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT LABS	5GM/100ML;224MG/100ML; 450MG/100ML	N18362 002

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT LABS	5GM/100ML;224MG/100ML; 900MG/100ML‡	N19691 007 MAR 24, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT LABS	5GM/100ML;224MG/100ML; 225MG/100ML‡	N18365 003 JUL 05, 1983

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
ABBOTT LABS 5GM/100ML;224MG/100ML; 300MG/100ML N18876 003 JAN 17, 1986

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP TRAVENOL LABS 5GM/100ML;224MG/100ML; 900MG/100ML‡ N19308 006 APR 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP ABBOTT LABS 5GM/100ML;298MG/100ML; 450MG/100ML N18362 003

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP ABBOTT LABS 5GM/100ML;298MG/100ML; 900MG/100ML‡ N19691 009 MAR 24, 1988

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
ABBOTT LABS 5GM/100ML;298MG/100ML; 225MG/100ML‡ N18365 004 JUL 05, 1983

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
ABBOTT LABS 5GM/100ML;298MG/100ML; 300MG/100ML‡ N18876 004 MAR 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP ABBOTT LABS 5GM/100ML;74.5MG/100ML; 450MG/100ML‡ N18362 008 MAR 28, 1988
AP 5GM/100ML;149MG/100ML; 450MG/100ML‡ N18362 004 MAR 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP ABBOTT LABS 5GM/100ML;74.5MG/100ML; 900MG/100ML‡ N19691 001 MAR 24, 1988
AP 5GM/100ML;149MG/100ML; 900MG/100ML‡ N19691 003 MAR 24, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
ABBOTT LABS 5GM/100ML;74.5MG/100ML; 225MG/100ML‡ N18365 005 MAR 28, 1988
5GM/100ML;149MG/100ML; 225MG/100ML‡ N18365 007 MAR 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
ABBOTT LABS 5GM/100ML;74.5MG/100ML; 300MG/100ML‡ N18876 005 MAR 28, 1988
5GM/100ML;149MG/100ML; 300MG/100ML‡ N18876 009 MAR 28, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;110MG/100ML‡ N19631 011 FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;200MG/100ML‡ N19631 012 FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;330MG/100ML‡ N19631 013 FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
KENDALL MCGAW 10GM/100ML;450MG/100ML‡ N19631 014 FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP KENDALL MCGAW 10GM/100ML;900MG/100ML‡ N19631 015 FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
KENDALL MCGAW 2.5GM/100ML; 110MG/100ML‡ N19631 001 FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
KENDALL MCGAW 2.5GM/100ML; 200MG/100ML‡ N19631 002 FEB 24, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

	KENDALL MCGAW	2.5GM/100ML; 330MG/100ML‡	N19631 003	FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	2.5GM/100ML; 450MG/100ML‡	N19631 004	FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	KENDALL MCGAW	2.5GM/100ML; 900MG/100ML‡	N19631 005	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	KENDALL MCGAW	5GM/100ML;110MG/100ML‡	N19631 006	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	5GM/100ML;200MG/100ML‡	N19631 007	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	5GM/100ML;330MG/100ML‡	N19631 008	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	5GM/100ML;450MG/100ML‡	N19631 009	FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	KENDALL MCGAW	5GM/100ML;900MG/100ML‡	N19631 010	FEB 24, 1988

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

RENOCAL-76

AP	SQUIBB DIAGS	66%;10%‡	N89347 001	JUN 01, 1988

DIAZEPAM

TABLET; ORAL

DIAZEPAM

AB	PIONEER PHARMS	2MG‡	N70787 001	AUG 02, 1988
AB		5MG‡	N70788 001	AUG 02, 1988
AB		10MG‡	N70776 001	AUG 02, 1988

DIAZEPAM

TABLET; ORAL

Q-PAM

AB	QUANTUM PHARMCS	2MG‡	N72431 001	APR 29, 1988
AB		5MG‡	N72432 001	APR 29, 1988
AB		10MG‡	N72433 001	APR 29, 1988

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

MED MKTG SPEC	50MG		N17425 001
∂	100MG		N17425 002
/S/SCHERING/	/50MG/		/N17425/001/

INJECTABLE; INJECTION

DIAZOXIDE

AP	QUAD PHARMS	15MG/ML‡	N71908 001	JAN 26, 1988

SUSPENSION; ORAL

PROGLYCEM

MED MKTG SPEC	50MG/ML		N17453 001
/S/SCHERING/	/50MG/ML/		/N17453/001/

DICLOFENAC SODIUM

TABLET, ENTERIC COATED; ORAL

VOLTAREN

	CIBA PHARM	25MG‡	N19201 001	JUL 28, 1988
		50MG‡	N19201 002	JUL 28, 1988
		75MG‡	N19201 003	JUL 28, 1988

DICYCLOMINE HYDROCHLORIDE

SYRUP; ORAL

BENTYL

>ADD> AA	MERRELL DON	10MG/5ML	N07961 002	OCT 15, 1984	
>ADD>	DICYCLOMINE HCL				
>ADD> AA	BARRE NATL	10MG/5ML	N84479 001		

DIETHYLCARBAMAZINE CITRATE

TABLET; ORAL
/HETRAZAN/

	/LEDERLE/LABS/	/50MG/	/N06459/001/
	ə LEDERLE LABS	50MG	N06459 001

DIFLORASONE DIACETATE

CREAM; TOPICAL
/DIFLORASONE/DIACETATE/

	/UPJOHN/	/0.05%/	/N19259/001/ /AUG/28,/1985/
	ə UPJOHN	0.05%	N19259 001 AUG 28, 1985

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

>DLT>	/AA/	/LEDERLE/LABS/	/25MG/	/N86874/001/
>DLT>	/AA/		/50MG/	/N86875/001/
>ADD>		ə LEDERLE LABS	25MG	N86874 001
>ADD>		ə	50MG	N86875 001

DISOPYRAMIDE PHOSPHATE

CAPSULE, CONTROLLED RELEASE; ORAL
DISOPYRAMIDE PHOSPHATE

AB	KV PHARM	EQ 100MG BASE*	N71929 001 AUG 19, 1988

NORPACE CR

AB	SEARLE	EQ 100MG BASE	N18655 001 JUL 20, 1982

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER	80MG/100ML	N19615 001 MAR 27, 1987
AP		160MG/100ML	N19615 002 MAR 27, 1987
AP		320MG/100ML	N19615 003 MAR 27, 1987
		640MG/100ML	N19615 004 MAR 27, 1987

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

/AP/	/TRAVENOL/LABS/	/80MG/100ML/	/N19615/001/ /MAR/27,/1987/
/AP/		/160MG/100ML/	/N19615/002/ /MAR/27,/1987/
/AP/		/320MG/100ML/	/N19615/003/ /MAR/27,/1987/
		/640MG/100ML/	/N19615/004/ /MAR/27,/1987/

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL
ADAPIN

AB	PENNWALT	EQ 150MG BASE	N16987 007 APR 13, 1987

DOXEPIN HCL

AB	BARR LABS	EQ 25MG BASE*	N71502 001 FEB 18, 1988
AB		EQ 50MG BASE*	N71653 001 FEB 18, 1988
AB		EQ 75MG BASE*	N71654 001 FEB 18, 1988
AB		EQ 100MG BASE*	N71521 001 FEB 18, 1988
AB	CHELSEA LABS	EQ 75MG BASE*	N71763 001 FEB 09, 1988
AB		EQ 150MG BASE*	N71764 001 FEB 09, 1988
AB	LEDERLE LABS	EQ 10MG BASE*	N71685 001 JAN 05, 1988
AB		EQ 25MG BASE*	N71686 001 JAN 05, 1988
AB		EQ 50MG BASE*	N71673 001 JAN 05, 1988
AB		EQ 75MG BASE*	N71674 001 JAN 05, 1988
AB		EQ 100MG BASE*	N71675 001 JAN 05, 1988
AB		EQ 150MG BASE*	N71676 001 JAN 05, 1988
AB	PUREPAC PHARM	EQ 75MG BASE*	N72386 001 SEP 08, 1988
AB		EQ 100MG BASE*	N72110 001 SEP 08, 1988
AB		EQ 150MG BASE*	N72387 001 SEP 08, 1988

DOXEPIN HYDROCHLORIDE

CONCENTRATE; ORAL
DOXEPIN HCL

AA	MY K LABS	EQ 10MG BASE/ML	N71918 001 JUL 20, 1988

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE

AB	INTERPHARM	EQ 50MG BASE	N62763 001 SEP 02, 1988
AB		EQ 100MG BASE	N62763 002 SEP 02, 1988
AB	VITARINE	EQ 50MG BASE	N62780 001 APR 12, 1988

INJECTABLE; INJECTION
DOXYCYCLINE

AP	BEN VENUE LABS	EQ 100MG BASE/VIAL	N62569 001 MAR 09, 1988
AP		EQ 200MG BASE/VIAL	N62569 002 MAR 09, 1988

TABLET; ORAL
DOXYCYCLINE HYCLATE

AB	INTERPHARM	EQ 100MG BASE	N62764 001 SEP 02, 1988

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

AP	ABBOTT LABS	2.5MG/ML	N71981 001 FEB 29, 1988
>ADD > AP >ADD >	ASTRA PHARM PRODS	2.5MG/ML	N72018 001 OCT 20, 1988
>ADD > AP >ADD >		2.5MG/ML	N72019 001 OCT 19, 1988
>ADD > AP >ADD >		2.5MG/ML	N72020 001 OCT 19, 1988
>ADD > AP >ADD >		2.5MG/ML	N72021 001 OCT 19, 1988
AP	DUPONT CRI CARE	2.5MG/ML	N71645 001 APR 07, 1988
>ADD > AP >ADD >	LUITPOLD PHARMS	2.5MG/ML	N72123 001 OCT 24, 1988
>ADD > AP >ADD >		2.5MG/ML	N72335 001 OCT 24, 1988

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

AP	QUAD PHARMS	2.5MG/ML	N71941 001 AUG 17, 1988
AP		2.5MG/ML	N71942 001 AUG 17, 1988
AP	SOLOPAK LABS	2.5MG/ML	N71750 001 SEP 06, 1988
AP		2.5MG/ML	N71754 001 SEP 06, 1988
AP		2.5MG/ML	N71755 001 SEP 06, 1988

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE AND DROPERIDOL

AP	ABBOTT LABS	2.5MG/ML; EQ 0.05MG BASE/ML	N71982 001 MAY 04, 1988

INNOVAR

AP	JANSSEN PHARMA	2.5MG/ML; EQ 0.05MG BASE/ML	N16049 001

DYDROGESTERONE

>ADD >	TABLET; ORAL		
>ADD >	GYNOREST		
>ADD >	∂ KALI DUPHAR	5MG	N17388 001
>ADD >	∂	10MG	N17388 002
>DLT >	/TABLET;ORAL/		
>DLT >	/GYNOREST/		
>DLT >	/REID/ROWELL/	/5MG/	/N17388/001/
>DLT >		/10MG/	/N17388/002/

EDETATE CALCIUM DISODIUM

TABLET; ORAL
CALCIUM DISODIUM VERSENATE

>DLT >	/RIKER/LABS/	/500MG/	/N08922/002/
>ADD >	∂ RIKER LABS	500MG	N08922 002

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
REVERSOL

AP	ORGANON	10MG/ML	N89624 001 MAY 13, 1988

ENALAPRIL MALEATE

TABLET; ORAL
VASOTEC
MS&D RES LABS — 2.5MG — N18998 005 — JUL 26, 1988

ENALAPRILAT

INJECTABLE; INJECTION
VASOTEC
MS&D RES LABS — 1.25MG/ML — N19309 001 — FEB 09, 1988

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL AND EPINEPHRINE

AP	ABBOTT LABS	0.005MG/ML;0.5%	N89635 001	JUN 21, 1988
AP		0.005MG/ML;1%	N89649 001	JUN 21, 1988
AP		0.005MG/ML;1.5%	N89645 001	JUN 21, 1988
AP		0.005MG/ML;1.5%	N89650 001	JUN 21, 1988
AP		0.005MG/ML;2%	N89651 001	JUN 21, 1988
AP		0.01MG/ML;1%	N89644 001	JUN 21, 1988
AP		0.01MG/ML;2%	N89646 001	JUN 21, 1988

LIDOCAINE HCL W/ EPINEPHRINE

/AP/	/LEMMON/	/0.01MG/ML;1%/	/N85463/001/	
	ə LEMMON	0.01MG/ML;1%	N85463 001	

XYLOCAINE W/ EPINEPHRINE

AP	ASTRA PHARM PRODS	0.005MG/ML;0.5%	N06488 013	
AP		0.005MG/ML;1%	N06488 018	NOV 13, 1986
AP		0.005MG/ML;2%	N06488 019	NOV 13, 1986

ERGOLOID MESYLATES

TABLET; ORAL
/ERGOLOID MESYLATES/

/AB/	/CHELSEA LABS/	/1MG/	/N88207/001/	/MAR 22, 1984/

ERGOLOID MESYLATES

TABLET; ORAL
GERIMAL

AB	CHELSEA LABS	1MG	N88207 001	MAR 22, 1984

TABLET; SUBLINGUAL
/GERIMAL/

/AA/	/RIKER LABS/	/0.5MG/	/N84868/001/	
/AA/		/1MG/	/N85809/001/	
	ə RIKER LABS	0.5MG	N84868 001	
	ə	1MG	N85809 001	

/ERGOLOID MESYLATES/

/AA/	/CHELSEA LABS/	/0.5MG/	/N86189/001/	
/AA/		/1MG/	/N86188/001/	

GERIMAL

AA	CHELSEA LABS	0.5MG	N86189 001	
AA		1MG	N86188 001	

ERYTHROMYCIN

SOLUTION; TOPICAL
ERYTHROMYCIN

AT	NASKA PHARMA	2%	N62957 001	JUL 21, 1988

ETS-2%

AT	PADDOCK LABS	2%	N62687 001	FEB 05, 1988

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION; ORAL
ILOSONE SULFA
LILLY — EQ 125MG BASE/5ML; EQ 600MG BASE/5ML — N50599 001 — SEP 16, 1988

ERYTHROMYCIN ETHYLSUCCINATE

TABLET; ORAL
ERYTHROMYCIN ETHYLSUCCINATE

AB	MYLAN PHARMS	EQ 400MG BASE	N62847 001	SEP 14, 1988

TABLET, CHEWABLE; ORAL
ERYPED

AB	ABBOTT LABS	EQ 200MG BASE	N50297 003	JUL 05, 1988

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL
ERTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

AB	BARR LABS	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N62759 001 MAY 20, 1988
	ERYZOLE		
AB	ALRA LABS	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N62758 001 JUN 15, 1988
	PEDIAZOLE		
AB	ROSS LABS	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N50529 001

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION
ERYTHROCIN

AP	ABBOTT LABS	EQ 500MG BASE/VIAL	N62586 001 JAN 04, 1988
AP		EQ 1GM BASE/VIAL	N62586 002 JAN 04, 1988

ERYTHROMYCIN STEARATE

TABLET; ORAL
BRISTAMYCIN

AB	BRISTOL LABS	EQ 250MG BASE	N61304 001
AB		EQ 250MG BASE	N61887 001
	ERYPAR		
AB	PARKE DAVIS	EQ 250MG BASE	N62032 001
AB		EQ 500MG BASE	N62032 002
	ERYTHROCIN STEARATE		
AB	ABBOTT LABS	EQ 125MG BASE	N60359 002
	ERYTHROMYCIN STEARATE		
AB	LEDERLE LABS	EQ 250MG BASE	N62089 001
AB		EQ 500MG BASE	N62089 002
	PFIZER-E		
AB	PFIZER LABS	EQ 500MG BASE	N61791 002

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC

	DUPONT CRI CARE	10MG/ML	N19386 001 AUG 15, 1988

ESTRADIOL

FILM, CONTROLLED RELEASE; PERCUTANEOUS
ESTRADERM

	CIBA PHARM	0.05MG/24HR	N19081 002 SEP 10, 1986
		0.1MG/24HR	N19081 003 SEP 10, 1986

ESTRONE

INJECTABLE; INJECTION
ESTRONE

BP	STERIS LABS	5MG/ML	N85239 001
	THEELIN		
BP	PARKE DAVIS	1MG/ML	N03977 001
BP		5MG/ML	N03977 003

ETHINYL ESTRADIOL

TABLET; ORAL
LYNORAL

> DLT > BP	ORGANON	0.05MG	N05490 002
> DLT > BP		0.01MG	N05490 003
> ADD >	ORGANON	0.01MG	N05490 003
> ADD >		0.05MG	N05490 002

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/35E-21

AB	SEARLE PHARMS	0.035MG;1MG	N71480 001 APR 12, 1988

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHINDRONE AND ETHINYL ESTRADIOL

AB	NATSON LABS	0.035MG;0.5MG AND 1MG*	N71043 001 APR 01, 1988

ORTHO-NOVUM 10/11-21

AB	ORTHO PHARM	0.035MG;0.5MG AND 1MG	N18354 001 JAN 11, 1982

TABLET; ORAL-28

NORETHIN 1/35E-28

AB	SEARLE PHARMS	0.035MG;1MG*	N71481 001 APR 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

AB	NATSON LABS	0.035MG;0.5MG AND 1MG*	N71044 001 APR 01, 1988

ORTHO-NOVUM 10/11-28

AB	ORTHO PHARM	0.035MG;0.5MG AND 1MG	N18354 002 JAN 11, 1982

ETHIODIZED OIL

/INJECTABLE;/INJECTION/
/ETHIODOL/
/FOUGERA/ /99%/ /N09190/001/

OIL; INTRALYMPHATIC, INTRAUTERINE

ETHIODOL

	SAVAGE LABS	99%	N09190 001

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

AB	AM THERPTCS	EQ 200MG BASE*		N72307 001 AUG 22, 1988
AB		EQ 300MG BASE*		N72308 001 AUG 22, 1988
>ADD> AB	CORD LABS	EQ 200MG BASE*		N72394 001 OCT 17, 1988
>ADD> AB		EQ 300MG BASE*		N72395 001 OCT 17, 1988
AB	HALSEY DRUG	EQ 200MG BASE*	AUG 17, 1988 :	JUL 05, 1988
AB		EQ 300MG BASE*	AUG 17, 1988 :	JUL 05, 1988
AB	PAR PHARM	EQ 200MG BASE*		N72437 001 AUG 22, 1988
AB		EQ 300MG BASE*		N72438 001 AUG 22, 1988
AB	QUANTUM PHARMCS	EQ 200MG BASE*	AUG 17, 1988 :	APR 14, 1988
AB		EQ 300MG BASE*	AUG 17, 1988 :	APR 14, 1988
AB	NATSON LABS	EQ 200MG BASE*	AUG 17, 1988 :	JUL 08, 1988
AB		EQ 300MG BASE*	AUG 17, 1988 :	JUL 08, 1988

NALFON

AB	DISTA PRODS	EQ 300MG BASE	N17604 002

NALFON 200

AB	DISTA PRODS	EQ 200MG BASE	N17604 003

TABLET; ORAL

FENOPROFEN CALCIUM

AB	AM THERPTCS	EQ 600MG BASE*	AUG 17, 1988 :	N72309 001 JUN 16, 1988
AB	CHELSEA LABS	EQ 600MG BASE*	AUG 17, 1988 :	N72407 001 JUN 13, 1988
>ADD> AB	CORD LABS	EQ 600MG BASE*		N72396 001 OCT 17, 1988
AB	DANBURY PHARMA	EQ 600MG BASE*		N72602 001 OCT 11, 1988
AB	HALSEY DRUG	EQ 600MG BASE*	AUG 17, 1988 :	N72357 001 JUL 05, 1988
AB	LEDERLE LABS	EQ 600MG BASE*	AUG 17, 1988 :	N72326 001 APR 20, 1988
AB	MYLAN PHARMS	EQ 600MG BASE*	AUG 17, 1988 :	N72267 001 JUN 08, 1988
AB	PAR PHARM	EQ 600MG BASE*	AUG 17, 1988 :	N72429 001 JUL 19, 1988
AB	PHARM BASICS	EQ 600MG BASE*	AUG 17, 1988 :	N72362 001 JUN 16, 1988
AB	PUREPAC PHARM	EQ 600MG BASE*		N72274 001 MAY 02, 1988
AB	QUANTUM PHARMCS	EQ 600MG BASE*	AUG 17, 1988 :	N72194 001 APR 14, 1988
AB	NATSON LABS	EQ 600MG BASE*	AUG 17, 1988 :	N72165 001 JUL 08, 1988
AB	ZENITH LABS	EQ 600MG BASE*		N72557 001 AUG 29, 1988

NALFON

AB	DISTA PRODS	EQ 600MG BASE	N17710 001

FERROUS SULFATE; FOLIC ACID

>DLT>	/CAPSULE;ORAL/			
>DLT>	/FOLVRON/			
>DLT>	/LEDERLE LABS/	/182MG;0.33MG/		/N06012/003/
>ADD>	@ LEDERLE LABS	182MG;0.33MG		N06012 003

FLECAINIDE ACETATE

TABLET; ORAL
TAMBOCOR

	RIKER LABS	50MG	N18830 004 AUG 23, 1988
		150MG	N18830 003 JUN 03, 1988

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

AT	G&W LABS	0.01%	N89526 001 JUL 26, 1988
AT		0.025%	N89525 001 JUL 26, 1988

OIL; TOPICAL
DERMA-SMOOTHE/FS

	HILL DERM	0.01%	N19452 001 FEB 03, 1988

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE

AT	G&W LABS	0.025%	N89524 001 JUL 26, 1988

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE

AB	CLAY PARK LABS	0.05%	N71790 001 JUL 13, 1988 : APR 25, 1988

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL

AP	BEN VENUE LABS	50MG/ML	N89508 001 JAN 26, 1988

FLUPHENAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
FLUPHENAZINE HCL

AP	QUAD PHARMS	2.5MG/ML	N89800 001 JUN 08, 1988

TABLET; ORAL
FLUPHENAZINE HCL

AB	MYLAN PHARMS	1MG	N89801 001 AUG 12, 1988
AB		2.5MG	N89802 001 AUG 12, 1988
AB		5MG	N89803 001 AUG 12, 1988
AB		10MG	N89804 001 AUG 12, 1988
AB	PAR PHARM	1MG	N89740 001 AUG 25, 1988
AB		2.5MG	N89741 001 AUG 25, 1988
AB		5MG	N89742 001 AUG 25, 1988
AB		10MG	N89743 001 AUG 25, 1988

PERMITIL

BP	SCHERING	2.5MG	N12034 004
BP		5MG	N12034 005
BP		10MG	N12034 006
/S/		/2.5MG/	/N12034/004/
/S/		/5MG/	/N12034/005/
/S/		/10MG/	/N12034/006/

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL
FLURAZEPAM HCL

AB	HALSEY DRUG	15MG	N71808 001 JAN 07, 1988
AB		30MG	N71809 001 JAN 07, 1988
AB	SUPERPHARM	15MG	N71659 001 AUG 04, 1988
AB		30MG	N71660 001 AUG 04, 1988

> ADD > FLURBIPROFEN

> ADD > TABLET; ORAL
> ADD > ANSAID
> ADD > UPJOHN 50MG 'N18766 002
> ADD > OCT 31, 1988
> ADD > 100MG 'N18766 003
> ADD > OCT 31, 1988

FOLIC ACID

TABLET; ORAL
FOLIC ACID
/AA/ /BARR LABS/ /1MG/ /N89177/001/
/JAN 08, 1986/
∂ BARR LABS 1MG N89177 001
JAN 08, 1986

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE
/AP/ /PARKE/DAVIS/ /10MG/ML/ /N18420/001/
/FEB 26, 1982/
AP WARNER CHILCOTT 10MG/ML N18420 001
FEB 26, 1982

TABLET; ORAL
FUROSEMIDE
AB BARR LABS 80MG 'N70100 001
JAN 26, 1988
AB DANBURY PHARMA 80MG 'N71594 001
FEB 09, 1988

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION
MAGNEVIST
BERLEX LABS 469.01MG/ML 'N19596 001
JUN 02, 1988

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION
GALLIUM CITRATE GA 67
/MEDI PHYSICS/ /1MCI/ML/ /N17700/001/
∂ MEDI PHYSICS 1MCI/ML N17700 001

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC
PRED-G
ALLERGAN PHARMS EQ 0.3% BASE;1% 'N50586 001
JUN 10, 1988

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE
AP ABBOTT LABS 0.2MG/ML 'N89393 001
JUN 15, 1988

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN
> ADD > AT IPHARM 0.025MG/ML;EQ 1.75MG BASE/ML;
> ADD > 10,000 UNITS/ML 'N62818 001
> ADD > OCT 11, 1988

GUANABENZ ACETATE

TABLET; ORAL
/WYTENSIN/
/WYETH AYERST LABS/ /EQ 16MG BASE/ /N18587/003/
/SEP 07, 1982/
∂ WYETH AYERST LABS EQ 16MG BASE N18587 003
SEP 07, 1982

HALOPERIDOL

TABLET; ORAL
HALDOL SOLUTAB
/J/MCNEIL LABS/ /1MG/ /N17079/001/
∂ MCNEIL PHARM 1MG N17079 001
HALOPERIDOL
AB BARR LABS 5MG 'N71212 001
JAN 07, 1988
AB 10MG 'N71173 001
JAN 07, 1988
AB 20MG 'N71177 001
JAN 07, 1988

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

AB	BOLAR PHARM	0.5MG	N71571 001 JUN 03, 1988
AB		1MG	N71572 001 JUN 03, 1988
AB		2MG	N71573 001 JUN 03, 1988
AB		5MG	N71374 001 JUN 03, 1988
AB		10MG	N71375 001 JUN 03, 1988
AB		20MG	N71376 001 JUN 03, 1988
AB	CORD LABS	10MG	N71210 001 MAR 11, 1988
AB		20MG	N71211 001 MAR 11, 1988

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALDOL

/AA/	/MCNEIL/LABS/	/EQ 2MG BASE/ML/	/N15922/001/
AA	MCNEIL PHARM	EQ 2MG BASE/ML	N15922 001

HALOPERIDOL INTENSOL

AA	ROXANE LABS	EQ 2MG BASE/ML	N72045 001 APR 12, 1988

INJECTABLE; INJECTION

HALOPERIDOL

AP	LEMMON	EQ 5MG BASE/ML	N70713 001 MAY 17, 1988
AP		EQ 5MG BASE/ML	N70714 001 MAY 17, 1988
AP		EQ 5MG BASE/ML	N70744 001 MAY 17, 1988

HEPARIN SODIUM

INJECTABLE; INJECTION

HEP FLUSH KIT IN PLASTIC CONTAINER

AP	LYPHOMED	10 UNITS/ML	N17029 017 DEC 05, 1985
AP		100 UNITS/ML	N17029 018 DEC 05, 1985

HEPARIN LOCK FLUSH

/AP/	/ABBOTT/LABS/	/100 UNITS/ML/	/N05264/010/
	∂ ABBOTT LABS	100 UNITS/ML	N05264 010

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH IN PLASTIC CONTAINER

AP	ABBOTT LABS	10 UNITS/ML	N05264 015 MAY 21, 1985
AP		100 UNITS/ML	N05264 016 MAY 21, 1985

HEPARIN SODIUM

>DLT>/AP/	/LYPHOMED/	/5,000 UNITS/ML/	/N17979/003/
>ADD>	∂ LYPHOMED	5,000 UNITS/ML	N17979 003

HEPARIN SODIUM IN PLASTIC CONTAINER

AP	LYPHOMED	1,000 UNITS/ML	N17029 013 DEC 05, 1985
AP		5,000 UNITS/ML	N17029 014 DEC 05, 1985
AP		10,000 UNITS/ML	N17029 015 DEC 05, 1985
AP		20,000 UNITS/ML	N17029 016 DEC 05, 1985

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

/AP/	/ABBOTT/LABS/	/10,000 UNITS/100ML/	/N19339/003/ /MAR/27,/1985/
	∂ ABBOTT LABS	10,000 UNITS/100ML	N19339 003 MAR 27, 1985

HEPARIN SODIUM 1000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER	200 UNITS/100ML	N18609 001 APR 28, 1982
/AP/	/TRAVENOL/LABS/	/200 UNITS/100ML/	/N18609/001/ /APR/28,/1982/

/HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC/ /CONTAINER/

/AP/	/ABBOTT/LABS/	/5,000 UNITS/100ML/	/N19339/001/ /MAR/27,/1985/
	∂ ABBOTT LABS	5,000 UNITS/100ML	N19339 001 MAR 27, 1985

HEPARIN SODIUM 2000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER	200 UNITS/100ML	N18609 002 APR 28, 1982

/HEPARIN SODIUM 20000 UNITS AND SODIUM CHLORIDE 0.9% IN/ /PLASTIC CONTAINER/

/AP/	/TRAVENOL/LABS/	/200 UNITS/100ML/	/N18609/002/ /APR/28,/1982/

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

/AP/	/ABBOTT/LABS/	/5,000 UNITS/100ML/	/N19339/004/ /MAR/27,/1985/
/AP/		/10,000 UNITS/100ML/	/N19339/002/ /MAR/27,/1985/
	ə ABBOTT LABS	5,000 UNITS/100ML	N19339 004 MAR 27, 1985
	ə	10,000 UNITS/100ML	N19339 002 MAR 27, 1985

HEPARIN SODIUM 5000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER	500 UNITS/100ML	N18609 003 APR 28, 1982
/AP/	/TRAVENOL/LABS/	/500 UNITS/100ML/	/N18609/003/ /APR/28,/1982/

/LIQUAEMIN SODIUM PRESERVATIVE FREE/

/AP/	/ORGANON/	/1,000 UNITS/ML/	/N00552/011/ /APR/11,/1986/
/AP/		/5,000 UNITS/ML/	/N00552/012/ /APR/11,/1986/
/AP/		/10,000 UNITS/ML/	/N00552/013/ /APR/11,/1986/
	ə ORGANON	1,000 UNITS/ML	N00552 011 APR 11, 1986
	ə	5,000 UNITS/ML	N00552 012 APR 11, 1986
	ə	10,000 UNITS/ML	N00552 013 APR 11, 1986

SODIUM HEPARIN

/AP/	/LYPHOMED/	/5,000 UNITS/ML/	/N17033/002/
/AP/		/10,000 UNITS/ML/	/N17033/003/
/AP/		/20,000 UNITS/ML/	/N17033/004/
	ə LYPHOMED	5,000 UNITS/ML	N17033 002
	ə	10,000 UNITS/ML	N17033 003
	ə	20,000 UNITS/ML	N17033 004

NEXOCYCLIUM METHYLSULFATE

>DLT>	/TABLET;ORAL/		
>DLT>	/TRAL/		
>DLT>	/ə/ABBOTT/LABS/	/25MG/	/N10599/001/
>ADD>	TABLET; ORAL		
>ADD>	TRAL		
>ADD>	ABBOTT LABS	25MG	N10599 001

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HCL

/AA/	/PUREPAC/PHARM/	/50MG/	/N88178/001/ /AUG/15,/1983/
	ə PUREPAC PHARM	50MG	N88178 001 AUG 15, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRAL

AB	REID RONELL	25MG;25MG	N87608 001 FEB 08, 1982
AB		50MG;50MG	N87213 001 FEB 08, 1982
	/ə/	/25MG;25MG/	/N87608/001/ /FEB/08,/1982/
	/ə/	/50MG;50MG/	/N87213/001/ /FEB/08,/1982/

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

/BP/	/REID/RONELL/	/25MG;15MG;0.1MG/	/N87216/001/
BP	REID RONELL	25MG;15MG;0.1MG	N88376 001 OCT 28, 1983
	ə	25MG;15MG;0.1MG	N87210 001
	/ə/	/25MG;15MG;0.1MG/	/N88376/001/ /OCT/28,/1983/

/RESERPINE;/HYDROCHLOROTHIAZIDE;/AND/HYDRALAZINE/HCL/

/BP/	/LEDERLE/LABS/	/25MG;15MG;0.1MG/	/N87709/001/ /MAY/13,/1982/
	ə LEDERLE LABS	25MG;15MG;0.1MG	N87709 001 MAY 13, 1982

HYDROCHLOROTHIAZIDE

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE

AA	MY K LABS	50MG/5ML*	N89661 001 JUN 20, 1988
AA	ROXANE LABS	50MG/5ML	N88587 001 JUL 02, 1984

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

/AB/	/BANMAX PHARMS/	/25MG/	/N86369/001/
/AB/		/50MG/	/N83554/001/
	ə BANMAX PHARMS	25MG	N86369 001
	ə	50MG	N83554 001

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE

	/SCHERING/	/25MG;400MG/	/N19046/004/ /APR 06, 1987/
	ə SCHERING	25MG;400MG	N19046 004 APR 06, 1987

TRANDATE HCT

AB	GLAXO	25MG;100MG	N19174 001 APR 10, 1987
AB		25MG;200MG	N19174 002 APR 10, 1987
AB		25MG;300MG	N19174 003 APR 10, 1987
AB		25MG;400MG	N19174 004 APR 10, 1987

/TRANDATE-HCT/

/AB/	/GLAXO/	/25MG;100MG/	/N19174/001/ /APR 10, 1987/
/AB/		/25MG;200MG/	/N19174/002/ /APR 10, 1987/
/AB/		/25MG;300MG/	/N19174/003/ /APR 10, 1987/
/AB/		/25MG;400MG/	/N19174/004/ /APR 10, 1987/

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

AB	NOVOPHARM	15MG;250MG	N71819 001 APR 08, 1988
AB		25MG;250MG	N71820 001 APR 08, 1988
AB		30MG;500MG	N71821 001 APR 08, 1988
AB		50MG;500MG	N71822 001 APR 08, 1988

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

/AB/	/PUREPAC PHARM/	/50MG;500MG/	/N70689/001/ /APR 24, 1986/
	ə PUREPAC PHARM	50MG;500MG	N70689 001 APR 24, 1986
AB	WATSON LABS	15MG;250MG	N71920 001 AUG 29, 1988
AB		25MG;250MG	N71921 001 AUG 29, 1988
AB		30MG;500MG	N71922 001 AUG 29, 1988
AB		50MG;500MG	N71923 001 AUG 29, 1988
AB	ZENITH LABS	15MG;250MG	N71458 001 MAR 08, 1988
AB		25MG;250MG	N71459 001 MAR 08, 1988
AB		30MG;500MG	N71460 001 MAR 08, 1988
AB		50MG;500MG	N71461 001 MAR 08, 1988

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL

/VISKAZIDE/

	/SANDOZ PHARMS/	/25MG;5MG/	/N18872/001/ /JUL 22, 1987/
	ə SANDOZ PHARMS	25MG;5MG	N18872 001 JUL 22, 1987
		/25MG;10MG/	/N18872/002/ /JUL 22, 1987/
	ə	25MG;10MG	N18872 002 JUL 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE

AB	SIDMAK LABS	25MG;40MG	N72042 001 MAR 14, 1988
AB		25MG;80MG	N72043 001 MAR 14, 1988
AB	WARNER CHILCOTT	25MG;40MG	N71771 001 JAN 26, 1988
AB		25MG;80MG	N71772 001 JAN 26, 1988

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDROCHLOROTHIAZIDE W/ RESERPINE

/3/	/BOOTS/PHARMS/	/25MG;0.125MG/	/N85421/001/
ə	PHARMAFAIR	25MG;0.125MG	N85421 001

RESERPINE AND HYDROCHLOROTHIAZIDE

/BP/	/BARR/LABS/	/25MG;0.125MG/	/N84580/001/
/BP/		/50MG;0.125MG/	/N84579/001/
ə	BARR LABS	25MG;0.125MG	N84580 001
ə		50MG;0.125MG	N84579 001

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

/AA/	/LEDERLE/LABS/	/25MG;25MG/	/N87511/001/
ə	LEDERLE LABS	25MG;25MG	N87511 001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	VITARINE	25MG;50MG	N71737 001 FEB 12, 1988

TABLET; ORAL

MAXZIDE-25MG

	MYLAN PHARMS	25MG;37.5MG	N19129 003 MAY 13, 1988

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	CORD LABS	50MG;75MG	N72011 001 JUN 17, 1988
AB	DANBURY PHARMA	50MG;75MG	N71969 001 APR 17, 1988 : JAN 15, 1988
AB	PAR PHARM	50MG;75MG	N72337 001 MAY 11, 1988
AB	QUANTUM PHARMCS	50MG;75MG	N71980 001 APR 17, 1988 : FEB 01, 1988

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT	NASKA PHARMA	1%	N89706 001 MAR 10, 1988
AT		2.5%	N89682 001 MAR 10, 1988
AT	NMC LABS	1%	N87795 001 MAY 03, 1983

HYDROCORTISONE

CREAM; TOPICAL

HYDROTEX

AT	SYOSSET LABS	1%	N87427 001 APR 04, 1988

/AT/	/NMC/LABS/	/1%/	/N87795/001/ /MAY/03,/1983/

LOTION; TOPICAL

BETA-HC

AT	BETA DERM	1%	N89495 001 JAN 25, 1988

HYDROCORTISONE

AT	NASKA PHARMA	1%	N89705 001 APR 25, 1988

OINTMENT; TOPICAL

HC (HYDROCORTISONE)

/3/	/C&M/PHARMA/	/0.5%/	/N80481/001/
/3/		/1%/	/N80481/002/
AT	C&M PHARMA	1%	N80481 002

HYDROCORTISONE

AT	NASKA PHARMA	1%	N89704 001 MAR 10, 1988

TABLET; ORAL

HYDROCORTISONE

/BP/	/BARR/LABS/	/20MG/	/N83999/001/
ə	BARR LABS	20MG	N83999 001

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HYDROCORTISONE ACETATE

	/THANES/PHARMA/	/1%/	/N89472/001/ /JUN/13,/1988/

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL; TOPICAL

EPIFOAM

AT	REED & CARNRICK	1%;1%	N86457 001

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%

AT	COPLEY PHARM	1%;1%	N89440 001 MAY 17, 1988

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

	CARMOL HC		
AT	SYNTEX LABS	1%;10%	N80505 001
	HYDROCORTISONE ACETATE		
AT	THAMES PHARMA	1%;10%	N89472 001 JUN 13, 1988

HYDROCORTISONE BUTYRATE

SOLUTION; TOPICAL

	HYDROCORTISONE BUTYRATE		
AT	GIST BROCADES	0.1%	N19116 001 FEB 25, 1987
	LOCOID		
AT	OWEN LABS	0.1%‡	N19819 001 OCT 15, 1988

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

	NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE		
AT	STERIS LABS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML‡	N62874 001 MAY 11, 1988

HYDROFLUMETHIAZIDE

TABLET; ORAL

	HYDROFLUMETHIAZIDE		
∂	BOLAR PHARM	50MG	N88031 001 APR 06, 1983

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDROXYZINE HCL		
∂	ALTANA	25MG/ML	N87273 001 APR 20, 1982
∂		50MG/ML	N87273 002 APR 20, 1982

SYRUP; ORAL

	HYDROXYZINE HCL		
AA	NASKA PHARMA	10MG/5ML‡	N88785 001 FEB 03, 1988

TABLET; ORAL

	HYDROXYZINE HCL		
AB	HALSEY DRUG	10MG‡	N89366 001 MAY 02, 1988
AB		25MG‡	N89117 001 MAY 02, 1988
AB		50MG‡	N89396 001 MAY 02, 1988

IBUPROFEN

TABLET; ORAL

	IBU-TAB		
AB	ALRA LABS	400MG‡	N71058 001 AUG 11, 1988
AB		600MG‡	N71059 001 AUG 11, 1988
AB		800MG‡	N71965 001 AUG 11, 1988
	IBUPROFEN		
AB	HALSEY DRUG	800MG‡	N72137 001 FEB 05, 1988
AB	INVAMED	400MG‡	N72064 001 JAN 14, 1988
AB		600MG‡	N72065 001 JAN 14, 1988
AB		800MG‡	N71938 001 JAN 14, 1988
AB	MEDICOPHARMA	400MG‡	N71644 001 FEB 01, 1988
AB	PRIVATE FMLTNS	800MG‡	N72300 001 JUL 01, 1988
AB	PUREPAC PHARM	800MG‡	N71964 001 FEB 01, 1988

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL
IMIPRAMINE HCL

> DLT >	/AB/	/LEDERLE/LABS/	/10MG/	/N86269/001/
> DLT >	/AB/		/25MG/	/N86267/001/
> DLT >	/AB/		/50MG/	/N86268/001/
> ADD >		ə LEDERLE LABS	10MG	N86269 001
> ADD >		ə	25MG	N86267 001
> ADD >		ə	50MG	N86268 001
		/IMIPRAMINE/		
	/AB/	/BANMAX/PHARMS/	/10MG/	/N83827/001/
	/AB/		/25MG/	/N83827/002/
	/BP/		/50MG/	/N83827/003/
		ə BANMAX PHARMS	10MG	N83827 001
		ə	25MG	N83827 002
		ə	50MG	N83827 003

INDIUM IN-111 OXYQUINOLINE

/INJECTABLE;/INJECTION/
/INDIUM/IN-111/OXYQUINOLINE/

/AMERSHAM/	/N/A/	/N19044/001/	
		/DEC/23,/1985/	

INJECTABLE; INTRATHECAL
INDIUM IN-111 OXYQUINOLINE

AMERSHAM	1MCI/ML	N19044 001
		DEC 23, 1985

INDOCYANINE GREEN

INJECTABLE; INJECTION
CARDIO-GREEN

ə B-D MICROBIOL SYS	10MG/VIAL	N11525 003
	25MG/VIAL	N11525 001
ə	40MG/VIAL	N11525 004
	50MG/VIAL	N11525 002
/HYNSN/WES/A/DUN/	/10MG/VIAL/	/N11525/003/
	/50MG/VIAL/	/N11525/004/

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

AB	NOVOPHARM	25MG	N71342 001
			APR 18, 1988
AB		50MG	N71343 001
			APR 18, 1988

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

AB	VITARINE	25MG	N71711 001
			JUL 05, 1988
AB		50MG	N71712 001
			JUL 05, 1988

INSULIN PORK

INJECTABLE; INJECTION
/ILETIN/

/LILLY/	/500/UNITS/ML/	/N17931/001/
ILETIN I		
LILLY	500 UNITS/ML	N17931 001

IOHEXOL

INJECTABLE; INJECTION
OMNIPAGUE 180

AP	STERLING DRUG	38.8%	N18956 001
			DEC 26, 1985
/3/		/38.8%/	/N18956/001/
			/DEC/26,/1985/

IOTHALAMATE MEGLUMINE

SOLUTION; INTRAVESICAL
CYSTO-CONRAY II

MALLINCKRODT	17.2%	N17057 002

SOLUTION; INTRAVESICAL, URETERAL
CYSTO-CONRAY

MALLINCKRODT	43%	N17057 001

/SOLUTION;/URETHRAL/		
/CYSTO-CONRAY/		
/MALLINCKRODT/	/43%/	/N17057/001/
/CYSTO-CONRAY/II/		
/MALLINCKRODT/	/17.2%/	/N17057/002/

IRON DEXTRAN

INJECTABLE; INJECTION
/PROFERDEX/

/AP/	/FISONS/	/EQ 50MG IRON/ML/	/N17807/001/
	ə FISONS	EQ 50MG IRON/ML	N17807 001

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

> ADD >		QUAD PHARMS	100MG/ML‡	N89816 001 OCT 28, 1988

NYDRAZID

> ADD >	AP	SQUIBB	100MG/ML	N08662 001

TABLET; ORAL

> DLT >		/DON-ISONIAZID/		
> DLT >	AA	/DON PHARMS/	/300MG/	/N80330 002/
> ADD >		∂ DON PHARMS	300MG	N80330 002

LANIAZID

	AA	LANNETT	300MG‡	N89776 001 JUN 13, 1988

ISOSORBIDE DINITRATE

CAPSULE, CONTROLLED RELEASE; ORAL

DILATRATE-SR

	BC	REED & CARNICK	40MG‡	N19790 001 SEP 02, 1988

ISORDIL

	BC	WYETH AYERST LABS	40MG	N12882 002 JUL 29, 1988

TABLET; ORAL

ISORDIL

	AB	WYETH AYERST LABS	5MG‡	N12093 007 JUL 29, 1988
	AB		10MG‡	N12093 002 JUL 29, 1988
	AB		20MG‡	N12093 006 JUL 29, 1988
	AB		30MG‡	N12093 005 JUL 29, 1988
			40MG‡	N12093 001 JUL 29, 1988

ISOSORBIDE DINITRATE

	AB	BARR LABS	30MG‡	N87564 001 SEP 18, 1986
	AB	CORD LABS	5MG‡	N86221 001 JAN 07, 1988
	AB		10MG‡	N86223 001 JAN 07, 1988
	AB		20MG‡	N89367 001 APR 07, 1988
	AB	DANBURY PHARMA	5MG‡	N86034 001 JAN 06, 1988
	AB		10MG‡	N86032 001 JAN 07, 1988

ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE

	AB	PAR PHARM	30MG‡	N87946 001 JAN 12, 1988

TABLET; SUBLINGUAL

ISORDIL

	AB	WYETH AYERST LABS	2.5MG‡	N12940 004 JUL 29, 1988
	AB		5MG‡	N12940 003 JUL 29, 1988
	AB		10MG‡	N12940 005 JUL 29, 1988
			5MG‡	N12940 002

ISOSORBIDE DINITRATE

	AB	BARR LABS	10MG	N87545 001 SEP 18, 1986
	AB	CORD LABS	2.5MG‡	N86225 001 FEB 19, 1988
	AB		5MG‡	N86222 001 FEB 19, 1988
	AB	DANBURY PHARMA	2.5MG‡	N86033 001 FEB 26, 1988
	AB		5MG	N86031 001 SEP 29, 1987

TABLET, CONTROLLED RELEASE; ORAL

ISORDIL

		WYETH AYERST LABS	40MG‡	N12882 001 JUL 29, 1988

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR

	AP	PARKE DAVIS	EQ 10MG BASE/ML	N16812 001
	AP		EQ 50MG BASE/ML	N16812 002
	AP		EQ 100MG BASE/ML	N16812 003

KETAMINE HCL

	AP	QUAD PHARMS	EQ 10MG BASE/ML‡	N71949 001 APR 11, 1988
	AP		EQ 50MG BASE/ML‡	N71950 001 APR 11, 1988
	AP		EQ 100MG BASE/ML‡	N71951 001 APR 11, 1988

LACTULOSE

SYRUP; ORAL

	CEPHULAC			
/AA/	/MERRELL DON/	/10GM/15ML/	/N17657/001/	> ADD >
	CHRONULAC			> ADD >
AA	MERRELL DON	10GM/15ML	N17884 001	> ADD >
	CONSTILAC			> ADD >
AA	ALRA LABS	10GM/15ML‡	N71054 001 JUL 26, 1988	> ADD >
	CONSTULOSE			
AA	BARRE NATL	10GM/15ML‡	N70288 001 AUG 15, 1988	
	LACTULOSE			
AA	MY K LABS	10GM/15ML‡	N71841 001 SEP 22, 1988	
/AA/	/ROXANE LABS/	/10GM/15ML/	/N17906/001/	

SYRUP; ORAL, RECTAL

	CEPHULAC		
AA	MERRELL DON	10GM/15ML	N17657 001
	CHOLAC		
AA	ALRA LABS	10GM/15ML‡	N71331 001 JUL 26, 1988
	ENULOSE		
AA	BARRE NATL	10GM/15ML‡	N71548 001 AUG 15, 1988
	GENERLAC		
AA	MY K LABS	10GM/15ML‡	N71842 001 SEP 27, 1988
	LACTULOSE		
AA	KALI DUPHAR	10GM/15ML	N17906 001

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

	LEUCOVORIN CALCIUM		
AP	BEN VENUE LABS	EQ 100MG BASE/VIAL‡	N89717 001 MAR 28, 1988
AP	INTL PHARM	EQ 3MG BASE/ML‡	N89352 001 JUN 01, 1988
AP		EQ 50MG BASE/VIAL‡	N89353 001 JUN 01, 1988
AP	LEDERLE LABS	EQ 3MG BASE/ML	N08107 001
AP		EQ 100MG BASE/VIAL‡	N08107 004 MAY 23, 1988
AP	QUAD PHARMS	EQ 100MG BASE/VIAL	N89636 001 DEC 24, 1987

LEVOCARNITINE

SOLUTION; ORAL

	CARNITOR		
AA	SIGMA TAU	1GM/10ML‡	N18948 002 APR 27, 1988
	VITACARN		
AA	KENDALL MCGAW	1GM/10ML	N19257 001 APR 10, 1986

LEVODOPA

CAPSULE; ORAL

	BENDOPA		
/BD/	/ICN PHARMS/	/100MG/	/N16948/003/
/BD/		/250MG/	/N16948/001/
/BD/		/500MG/	/N16948/002/
	∂ ICN PHARMS	100MG	N16948 003
	∂	250MG	N16948 001
	∂	500MG	N16948 002

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	POLOCAINE W/ LEVONORDEFRIN		
AP	ASTRA PHARM PRODS	0.05MG/ML;2%‡	N89517 001 APR 14, 1988

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	LIDOCAINE HCL		
AP	ABBOTT LABS	20%‡	N89362 001 MAY 25, 1988
/AP/	/LEMMON/	/1%/	/N83627/001/
/AP/		/2%/	/N83627/002/
	∂ LEMMON	1%	N83627 001
	∂	2%	N83627 002

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

	LINCOCIN		
AP	UPJOHN	EQ 300MG BASE/ML	N50317 001
	LINCOMYCIN HCL		
AP	QUAD PHARMS	EQ 300MG BASE/ML‡	N62784 001 MAR 14, 1988

LISINOPRIL

TABLET; ORAL

	PRINIVIL			
AB	MS&D RES LABS	5MG	N19558 001	DEC 29, 1987
AB		10MG	N19558 002	DEC 29, 1987
AB		20MG	N19558 003	DEC 29, 1987
	ZESTRIL			
AB	IMPERIAL CHEM	5MG‡	N19777 001	MAY 19, 1988
AB		10MG‡	N19777 002	MAY 19, 1988
AB		20MG‡	N19777 003	MAY 19, 1988

LOPERAMIDE HYDROCHLORIDE

/SOLUTION;ORAL/

	/IMODIUM/			
	/JANSSEN/PHARMA/	/1MG/5ML/	/N19037/001/	
	∂ JANSSEN PHARMA	1MG/5ML	/JUL/31/1984/ N19037 001	JUL 31, 1984

LORAZEPAM

TABLET; ORAL

	LORAZEPAM			
AB	CORD LABS	0.5MG‡	N71193 001	APR 15, 1988
AB		1MG‡	N71194 001	APR 15, 1988
AB		2MG‡	N71195 001	APR 15, 1988
AB	WARNER CHILCOTT	1MG‡	N71038 001	JAN 12, 1988
AB		2MG‡	N71039 001	JAN 12, 1988

LOXAPINE SUCCINATE

CAPSULE; ORAL

	LOXAPINE SUCCINATE			
AB	WATSON LABS	EQ 5MG BASE‡	N72204 001	JUN 15, 1988
AB		EQ 10MG BASE‡	N72205 001	JUN 15, 1988
AB		EQ 25MG BASE‡	N72206 001	JUN 15, 1988
AB		EQ 50MG BASE‡	N72062 001	JUN 15, 1988
	LOXITANE			
AB	LEDERLE LABS	EQ 5MG BASE	N17525 001	
AB		EQ 10MG BASE	N17525 002	
AB		EQ 25MG BASE	N17525 003	
AB		EQ 50MG BASE	N17525 004	

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

	MAPROTILINE HCL			
AB	AM THERPTCS	25MG‡	N72129 001	JAN 14, 1988
AB		50MG‡	N72130 001	JAN 14, 1988
AB		75MG‡	N72131 001	JAN 14, 1988
> ADD > AB	MYLAN PHARMS	25MG‡	N72284 001	OCT 03, 1988
> ADD > AB		50MG‡	N72285 001	OCT 03, 1988
> ADD > AB		75MG‡	N72286 001	OCT 03, 1988
AB	WATSON LABS	25MG‡	N72162 001	JUN 01, 1988
AB		50MG‡	N72163 001	JUN 01, 1988
AB		75MG‡	N72164 001	JUN 01, 1988

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

	ANTIVERT			
AA	ROERIG	50MG	N10721 001	JAN 20, 1982
	MECLIZINE HCL			
AA	PAR PHARM	50MG‡	N89674 001	MAR 31, 1988

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

AB	PAR PHARM	EQ 50MG BASE	N72077 001 MAR 10, 1988
AB		EQ 100MG BASE	N72078 001 MAR 10, 1988
AB	PHARM BASICS	EQ 50MG BASE	N71007 001 MAR 25, 1988
AB		EQ 100MG BASE	N71008 001 MAR 25, 1988
AB	VITARINE	EQ 50MG BASE	N71710 001 JUN 15, 1988
AB		EQ 100MG BASE	N71684 001 JUN 15, 1988

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB	VITARINE	250MG	N72179 001 APR 21, 1988

PONSTEL

AB	PARKE DAVIS PR	250MG	N15034 003

MEGESTROL ACETATE

TABLET; ORAL

MEGESTROL ACETATE

AB	PAR PHARM	20MG	N72422 001 AUG 08, 1988
AB		40MG	N72423 001 AUG 08, 1988

MEPENZOLATE BROMIDE

/SOLUTION; ORAL/

/CANTIL/

	/MERRELL DOW/	/25MG/5ML/	/N10679/004/
	ə MERRELL DOW	25MG/5ML	N10679 004

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

/AA/	/MALLARD/	/400MG/	/N15072/002/
	ə MALLARD	400MG	N15072 002

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

/AA/	/PHARM/BASICS/	/200MG/	/N87825/001/ /MAR/18,/1982/
/AA/		/400MG/	/N87826/001/ /MAR/18,/1982/
	ə PHARM BASICS	200MG	N87825 001 MAR 18, 1982
	ə	400MG	N87826 001 MAR 18, 1982

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/50M-21

AB	SEARLE PHARMS	0.05MG;1MG	N71539 001 APR 12, 1988

NORETHINDRONE AND MESTRANOL

AB	WATSON LABS	0.05MG;1MG	N70758 001 JUL 01, 1988

TABLET; ORAL-28

NORETHIN 1/50M-28

AB	SEARLE PHARMS	0.05MG;1MG	N71540 001 APR 12, 1988

NORETHINDRONE AND MESTRANOL

AB	WATSON LABS	0.05MG;1MG	N70759 001 JUL 01, 1988

MESTRANOL; NORETHYNODREL

TABLET; ORAL-20

ENOVID

/AA/	/SEARLE/	/0.075MG;5MG/	/N10976/004/
	ə SEARLE	0.075MG;5MG	N10976 004

/ENOVID-E/

/AA/	/SEARLE/	/0.1MG;2.5MG/	/N10976/006/
	ə SEARLE	0.1MG;2.5MG	N10976 006

METAPROTERENOL SULFATE

SOLUTION; INHALATION

ALUPENT

AN	BOEHR INGEL	0.4%	N18761 002 OCT 10, 1986

DEY-DOSE

AN	DEY LABS	5%	N70805 001 AUG 17, 1987

METAPROTERENOL SULFATE

SOLUTION; INHALATION

	DEY-LUTE		
AN	DEY LABS	0.4%Ⓡ	N71786 001 AUG 05, 1988
AN		0.6%	N70804 001 AUG 17, 1987
		0.33%Ⓡ	N71806 001 AUG 05, 1988
		0.5%Ⓡ	N71805 001 AUG 05, 1988
	METAPROTERENOL SULFATE		
AN	ARMOUR PHARM	0.4%Ⓡ	N71275 001 JUL 27, 1988
AN		0.6%Ⓡ	N71018 001 JUL 27, 1988
/AN/	/DEY/LABS/	/0.6%/	/N70804/001/ /AUG/17,/1987/
/AN/		/5%/	/N70805/001/ /AUG/17,/1987/
AN	MY K LABS	5%Ⓡ	N72190 001 JUN 07, 1988
AN	PACO RES	0.4%Ⓡ	N71855 001 JUL 14, 1988
AN		0.6%Ⓡ	N71726 001 JUL 14, 1988

SYRUP; ORAL

	METSOL		
AA	MURO PHARM	10MG/5MLⓇ	N72023 001 SEP 15, 1988

TABLET; ORAL

	ALUPENT		
AB	BOEHR INGEL	10MG	N15874 002
AB		20MG	N15874 001
	METAPROTERENOL SULFATE		
AB	AM THERPTCS	10MGⓇ	N72054 001 JUN 23, 1988
AB		20MGⓇ	N72055 001 JUN 23, 1988
AB	PAR PHARM	10MGⓇ	N72024 001 JUN 28, 1988
AB		20MGⓇ	N72025 001 JUN 28, 1988
AB	PHARM BASICS	10MGⓇ	N71013 001 JAN 25, 1988
AB		20MGⓇ	N71014 001 JAN 25, 1988

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

	METHADONE		
AA	MALLINCKRODT	10MG/ML	N17116 002
	METHADONE HCL INTENSOL		
AA	ROXANE LABS	10MG/MLⓇ	N89897 001 SEP 06, 1988

METHIXENE HYDROCHLORIDE

>DLT>	/TABLET;/ORAL/		
>DLT>	/TEST/		
>DLT>	/DORSEY/LABS/	/1MG/	/N13420/001/
>ADD>	a DORSEY LABS	1MG	N13420 001

METHOCARBAMOL

TABLET; ORAL

	METHOCARBAMOL		
/AA/	/BARR/LABS/	/500MG/	/N84488/001/
	a BARR LABS	500MG	N84488 001

>DLT> /METHOTREXATE/

>DLT>	/TABLET;/ORAL/		
>DLT>	/METHOTREXATE/		
>DLT>	/LEDERLE/LABS/	/2.5MG/	/N08085/002/

METHOTREXATE SODIUM

INJECTABLE; INJECTION

	METHOTREXATE		
	LEDERLE LABS	EQ 1GM BASE/VIALⓇ	N11719 009 APR 07, 1988
	METHOTREXATE SODIUM		
AP	PHARMACHEMIE	EQ 25MG BASE/MLⓇ	N89158 001 JUL 08, 1988

>ADD>	TABLET; ORAL		
>ADD>	METHOTREXATE		
>ADD>	LEDERLE LABS	EQ 2.5MG BASE	N08085 002

METHOXSALEN

CAPSULE; ORAL

	/OXSORALEN/		
/BP/	/ELDER PHARMS/	/10MG/	/N09048 001/
	8-MOP		
	ELDER PHARMS	10MG	N09048 001

METHYCLOTHIAZIDE

TABLET; ORAL

	METHYCLOTHIAZIDE		
AB	CORD LABS	2.5MG	N89835 001 AUG 18, 1988
AB		5MG	N89837 001 AUG 18, 1988

METHYLDOPA

TABLET; ORAL

	METHYLDOPA		
AB	CORD LABS	125MG	N71700 001 MAR 02, 1988
AB	HALSEY DRUG	125MG	N71751 001 MAR 28, 1988
AB		250MG	N71752 001 MAR 28, 1988
AB		500MG	N71753 001 MAR 28, 1988
AB	SIDMAK LABS	125MG	N72126 001 JUL 07, 1988
AB		250MG	N72127 001 JUL 07, 1988
AB		500MG	N72128 001 JUL 07, 1988

METHYLPHENIDATE HYDROCHLORIDE

TABLET, CONTROLLED RELEASE; ORAL

	METHYLPHENIDATE HCL		
AB	MD PHARM	20MG	N89601 001 JUN 01, 1988
	RITALIN-SR		
AB	CIBA PHARM	20MG	N18029 001 MAR 30, 1982

METHYLPREDNISOLONE

TABLET; ORAL

	MEDROL		
AB	UPJOHN	24MG	N11153 005
AB		32MG	N11153 006
	METHYLPREDNISOLONE		
> ADD > AB	HEATHER DRUG	4MG	N85650 001
> DLT > /BP/		/4MG/	/N85650/001/
AB	PAR PHARM	16MG	N89207 001 APR 25, 1988
AB		24MG	N89208 001 APR 25, 1988
AB		32MG	N89209 001 APR 25, 1988

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	METOCLOPRAMIDE HCL		
AP	MAURRY BIOL	EQ 10MG BASE/2ML	N70892 001 AUG 26, 1988

SYRUP; ORAL

	METOCLOPRAMIDE HCL		
AA	BARRE NATL	EQ 5MG BASE/5ML	N71340 001 AUG 18, 1988

TABLET; ORAL

	CLOPRA		
AB	QUANTUM PHARMCS	EQ 5MG BASE	N72384 001 JUN 02, 1988
	METOCLOPRAMIDE HCL		
AB	SIDMAK LABS	EQ 10MG BASE	N71250 001 FEB 03, 1988
	REGLAN		
AB	ROBINS	EQ 5MG BASE	N17854 002 MAY 05, 1987

METOCURINE IODIDE

INJECTABLE; INJECTION

	METOCURINE IODIDE		
AP	QUAD PHARMS	2MG/ML	N89443 001 JUN 01, 1988
	METUBINE IODIDE		
AP	LILLY	2MG/ML	N06632 003

METOLAZONE

TABLET; ORAL
/MICROX/
/PENNHALT/ /0.5MG/ /N19532/001/ /OCT/30/1987/

MYKROX
FISONS 0.5MG N19532 001 OCT 30, 1987

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION
MEZLIN
MILES PHARM EQ 20GM BASE/VIAL* N50549 005 MAR 02, 1988
EQ 20GM BASE/VIAL* N62372 004 MAR 02, 1988

MINOXIDIL

SOLUTION; TOPICAL
ROGAINE
UPJOHN 2%* N19501 001 AUG 17, 1988

TABLET; ORAL
MINODYL
AB QUANTUM PHARMCS 2.5MG* N72153 001 JUL 13, 1988

MITOMYCIN

INJECTABLE; INJECTION
MUTAMYCIN
BRISTOL MYERS 40MG/VIAL* N62336 003 MAR 10, 1988

MORPHINE SULFATE

INJECTABLE; INJECTION
MORPHINE SULFATE
AP ABBOTT LABS 0.5MG/ML* N71849 001 MAY 11, 1988
AP 1MG/ML* N71850 001 MAY 11, 1988

MORPHINE SULFATE

TABLET, CONTROLLED RELEASE; ORAL
MS CONTIN
PURDUE FRDRK 60MG* N19516 002 APR 08, 1988

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCILLIN SODIUM
> ADD > AP MARSAM PHARMS EQ 500MG BASE/VIAL* N62844 001 OCT 26, 1988
> ADD > AP EQ 1GM BASE/VIAL* N62844 002 OCT 26, 1988
> ADD > AP EQ 2GM BASE/VIAL* N62844 004 OCT 26, 1988
> ADD > AP EQ 4GM BASE/VIAL* N62844 005 OCT 26, 1988
> ADD > AP EQ 10GM BASE/VIAL* N63008 001 SEP 29, 1988
> ADD > EQ 1.5GM BASE/VIAL* N62844 003 OCT 26, 1988

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL
NAFTIN
HERBERT LABS 1%* N19599 001 FEB 29, 1988

NALIDIXIC ACID

TABLET; ORAL
NALIDIXIC ACID
AB DANBURY PHARMA 250MG* N71936 001 JUN 29, 1988 : JUN 28, 1988
AB 500MG* N72061 001 JUN 29, 1988 : JUN 28, 1988
AB 1GM* N71919 001 JUN 29, 1988 : JUN 28, 1988

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION
NALOXONE HCL

AP	DUPONT CRI CARE	0.4MG/ML	N71083 001 JUL 28, 1988
AP		1MG/ML	N71084 001 JUL 28, 1988
AP		1MG/ML	N71311 001 JUL 28, 1988
AP	ELKINS SINN	0.02MG/ML	N71272 001 MAY 24, 1988
AP		1MG/ML	N71273 001 MAY 24, 1988
AP		1MG/ML	N71274 001 MAY 24, 1988
AP		1MG/ML	N71287 001 MAY 24, 1988
AP	INTL MEDTN SYS	1MG/ML	N72076 001 MAR 24, 1988
AP		1MG/ML	N72115 001 APR 27, 1988
AP	MARSAM PHARMS	0.4MG/ML	N71811 001 JUL 19, 1988

NITROFURANTOIN

/CAPSULE;/ORAL/
/NITROFURANTOIN/

	/BOLAR/PHARM/	/50MG/	/N84326/001/
	ə BOLAR PHARM	50MG	N84326 001
		/100MG/	/N84326/002/
	ə	100MG	N84326 002

TABLET; ORAL
NITROFURANTOIN

/AB/	/BOLAR/PHARM/	/100MG/	/N80447/002/
	ə BOLAR PHARM	100MG	N80447 002

NITROFURANTOIN SODIUM

> DLT >	/INJECTABLE;/INJECTION/			
> DLT >	/IVADANTIN/			
> DLT >	/NORWICH/EATON/	/EQ/180MG/BASE/VIAL/	/N12402/001/
> ADD >	ə NORWICH EATON	EQ 180MG BASE/VIAL	N12402 001

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
MACRODANTIN

AB	NORWICH EATON	50MG	N16620 001
AB		100MG	N16620 002

NITROFURANTOIN MACROCRYSTALLINE

AB	BOLAR PHARM	50MG	N70248 001 JUN 24, 1988
AB		100MG	N70249 001 JUN 24, 1988

NITROGLYCERIN

INJECTABLE; INJECTION
NITROGLYCERIN

AP	LUITPOLD PHARMS	5MG/ML	N71492 001 MAY 24, 1988
AP		5MG/ML	N72034 001 MAY 24, 1988

OINTMENT; TOPICAL
NITROGLYCERIN

	ALTANA	2%	N87355 001 JUL 08, 1988

NIZATIDINE

CAPSULE; ORAL
AXID

	LILLY	150MG	N19508 001 APR 12, 1988
		300MG	N19508 002 APR 12, 1988

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
AVENTYL HCL

BD	LILLY	EQ 10MG BASE	N14684 001
BD		EQ 25MG BASE	N14684 002
/BP/		/EQ/10MG/BASE/	/N14684/001/
/BP/		/EQ/25MG/BASE/	/N14684/002/

PAMELOR

BD	SANDOZ PHARMS	EQ 10MG BASE	N18013 001
BD		EQ 25MG BASE	N18013 002
/BP/		/EQ/10MG/BASE/	/N18013/001/
/BP/		/EQ/25MG/BASE/	/N18013/002/

NYSTATIN

CREAM; TOPICAL
NYSTATIN

AT	NASKA PHARMA	100,000 UNITS/GM	N62949 001	JUN 13, 1988

SUSPENSION; ORAL
NYSTATIN

AA	THAMES PHARMA	100,000 UNITS/ML	N62876 001	FEB 29, 1988

> ADD > OCTREOTIDE ACETATE

> ADD > INJECTABLE; INJECTION
> ADD > SANDOSTATIN

> ADD >	SANDOZ PHARMS	EQ 0.05MG BASE/ML	N19667 001	OCT 21, 1988
> ADD >		EQ 0.1MG BASE/ML	N19667 002	OCT 21, 1988
> ADD >		EQ 0.5MG BASE/ML	N19667 003	OCT 21, 1988

OXACILLIN SODIUM

INJECTABLE; INJECTION
BACTOCILL

AP	BEECHAM LABS	EQ 10GM BASE/VIAL	N61334 010	

OXACILLIN SODIUM

> ADD > AP	MARSAM PHARMS	EQ 250MG BASE/VIAL	N62856 001	OCT 26, 1988
> ADD > AP		EQ 500MG BASE/VIAL	N62856 002	OCT 26, 1988
> ADD > AP		EQ 1GM BASE/VIAL	N62856 003	OCT 26, 1988
> ADD > AP		EQ 2GM BASE/VIAL	N62856 004	OCT 26, 1988
> ADD > AP		EQ 4GM BASE/VIAL	N62856 005	OCT 26, 1988
AP		EQ 10GM BASE/VIAL	N62984 001	SEP 29, 1988

PROSTAPHLIN

> ADD > AP	BRISTOL LABS	EQ 250MG BASE/VIAL	N50195 001	
> ADD > AP		EQ 250MG BASE/VIAL	N61490 001	

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM

AB	AM THERPTCS	10MG	N71955 001	MAR 03, 1988
AB		15MG	N71956 001	MAR 03, 1988
AB		30MG	N71957 001	MAR 03, 1988
AB	BARR LABS	15MG	N71025 001	AUG 10, 1987
AB		30MG	N71026 001	AUG 10, 1987
/BP/		/15MG/	/N71025/001/	/AUG/10,/1987/
/BP/		/30MG/	/N71026/001/	/AUG/10,/1987/
AB	CHELSEA LABS	10MG	N71661 001	MAR 02, 1988
AB		15MG	N71662 001	MAR 02, 1988
AB		30MG	N71663 001	MAR 02, 1988
AB	CORD LABS	10MG	N71813 001	APR 19, 1988
AB		15MG	N71756 001	APR 19, 1988
AB		30MG	N71814 001	APR 19, 1988
/BP/	/MYLAN/PHARMS/	/10MG/	/N71713/001/	/OCT/20,/1987/
/BP/		/15MG/	/N71714/001/	/OCT/20,/1987/
/BP/		/30MG/	/N71715/001/	/OCT/20,/1987/
ə	MYLAN PHARMS	10MG	N71713 001	OCT 20, 1987
ə		15MG	N71714 001	OCT 20, 1987
ə		30MG	N71715 001	OCT 20, 1987
AB	PUREPAC PHARM	10MG	N72251 001	APR 14, 1988
AB		15MG	N72252 001	APR 14, 1988
AB		30MG	N72253 001	APR 14, 1988

OXAZEPAM

CAPSULE; ORAL

	OXAZEPAM		
AB	ZENITH LABS	10MG	N70943 001 AUG 03, 1987
AB		15MG	N70944 001 AUG 03, 1987
AB		30MG	N70945 001 AUG 03, 1987
/BP/		/10MG/	/N70943/001/ /AUG 03, 1987/
/BP/		/15MG/	/N70944/001/ /AUG 03, 1987/
/BP/		/30MG/	/N70945/001/ /AUG 03, 1987/
	SERAX		
AB	WYETH	10MG	N15539 002
AB		15MG	N15539 004
AB		30MG	N15539 006
/BP/		/10MG/	/N15539/002/
/BP/		/15MG/	/N15539/004/
/BP/		/30MG/	/N15539/006/
	ZAXOPAM		
AB	QUANTUM PHARMCS	10MG[X]	N70650 001 MAR 01, 1988
AB		15MG[X]	N70640 001 MAR 01, 1988
AB		30MG[X]	N70641 001 MAR 01, 1988

OXYBUTYNIN CHLORIDE

TABLET; ORAL

	DITROPAN		
AB	MARION LABS	5MG	N17577 001
	OXYBUTYNIN CHLORIDE		
AB	PHARM BASICS	5MG[X]	N70746 001 MAR 10, 1988

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET; ORAL

	DARICON		
	/BEECHAM/LABS/	/10MG/	/N11612/001/
	PFIZER LABS	10MG	N11612 001

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	OXYTETRACYCLINE HCL		
/AA/	/PUREPAC/PHARM/	/EQ 250MG BASE/	/N60634/001/
	③ PUREPAC PHARM	EQ 250MG BASE	N60634 001

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

	PANCURONIUM		
AP	ELKINS SINN	1MG/ML[X]	N72058 001 MAR 23, 1988
AP		2MG/ML[X]	N72059 001 MAR 23, 1988
AP		2MG/ML[X]	N72060 001 MAR 23, 1988
	PANCURONIUM BROMIDE		
AP	ASTRA PHARM PRODS	1MG/ML[X]	N72210 001 MAR 31, 1988
AP		2MG/ML[X]	N72211 001 MAR 31, 1988
AP		2MG/ML[X]	N72212 001 MAR 31, 1988
AP		2MG/ML[X]	N72213 001 MAR 31, 1988
AP	QUAD PHARMS	1MG/ML[X]	N72209 001 JUN 03, 1988
AP		2MG/ML[X]	N72208 001 JUN 03, 1988
	PAVULON		
AP	ORGANON	1MG/ML	N17015 002
AP		2MG/ML	N17015 001

PARAMETHADIONE

/CONCENTRATE;ORAL/

	/PARADIONE/		
/AA/	/ABBOTT/LABS/	/300MG/ML/	/N06800/002/

SOLUTION; ORAL

	PARADIONE		
AA	ABBOTT LABS	300MG/ML	N06800 002

PENICILLAMINE

CAPSULE; ORAL
CUPRIMINE
MS&D — 125MG — N19853 002
/125MG/ — /N50376/002/
250MG — N19853 001
/250MG/ — /N50376/001/

TABLET; ORAL
DEPEN 250
WALLACE LABS — 250MG — N19854 001
/250MG/ — /N50491/001/

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION
PENICILLIN G POTASSIUM

AP	MARSAM PHARMS	1,000,000 UNITS/VIAL	N62991 001 SEP 13, 1988
AP		5,000,000 UNITS/VIAL	N62991 002 SEP 13, 1988
AP		10,000,000 UNITS/VIAL	N62991 003 SEP 13, 1988
AP		20,000,000 UNITS/VIAL	N62991 004 SEP 13, 1988
AP	SQUIBB	10,000,000 UNITS/VIAL	N60362 004

POWDER FOR RECONSTITUTION; ORAL
PENICILLIN G POTASSIUM

/AA/	/PUREPAC/PHARM/	/400,000 UNITS/5ML/	/N61740/002/
	ə PUREPAC PHARM	400,000 UNITS/5ML	N61740 002

TABLET; ORAL
PENICILLIN G POTASSIUM

/AA/	/PUREPAC/PHARM/	/250,000 UNITS/	/N61588/002/
/AA/		/400,000 UNITS/	/N61588/003/
	ə PUREPAC PHARM	250,000 UNITS	N61588 002
	ə	400,000 UNITS	N61588 003

PENICILLIN G SODIUM

INJECTABLE; INJECTION
PENICILLIN G SODIUM

AP	MARSAM PHARMS	5,000,000 UNITS/VIAL	N63014 001 SEP 13, 1988	>DLT>
	/SQUIBB/SPA/	/5,000,000 UNITS/VIAL/	/N61935/001/	>DLT>
	SQUIBB SPA	5,000,000 UNITS/VIAL	N61935 001	>ADD>

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL
PENICILLIN V POTASSIUM

/AA/	/PUREPAC/PHARM/	/EQ 250MG BASE/5ML/	/N61758/002/
	ə PUREPAC PHARM	EQ 250MG BASE/5ML	N61758 002

TABLET; ORAL
PENICILLIN V POTASSIUM

/AA/	/PUREPAC/PHARM/	/EQ 250MG BASE/	/N61571/002/
/AA/		/EQ 500MG BASE/	/N61571/003/
	ə PUREPAC PHARM	EQ 250MG BASE	N61571 002
	ə	EQ 500MG BASE	N61571 003

PERPHENAZINE

/SYRUP;ORAL/
/TRILAFON/

	/SCHERING/	/2MG/5ML/	/N11294/002/
	ə SCHERING	2MG/5ML	N11294 002

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

/AA/	/BARR/LABS/	/35MG/	/N83644/001/
/AA/		/35MG/	/N83684/001/
/AA/		/35MG/	/N83686/001/
/AA/		/35MG/	/N83687/001/
/AA/		/35MG/	/N84831/001/
/AA/		/35MG/	/N84834/001/
/AA/		/35MG/	/N84835/001/
	ə BARR LABS	35MG	N83644 001
	ə	35MG	N83684 001
	ə	35MG	N83686 001
	ə	35MG	N83687 001
	ə	35MG	N84831 001
	ə	35MG	N84834 001
	ə	35MG	N84835 001

PHENMETRAZINE HYDROCHLORIDE

	/TABLET;ORAL/			
	/PRELUDIN/			
	/BOEHR/INGEL/	/25MG/	/N10460/005/	>DLT>
	ə BOEHR INGEL	25MG	N10460 005	>ADD>

PHENTERMINE RESIN COMPLEX

CAPSULE, CONTROLLED RELEASE; ORAL

	IONAMIN-30			
AB	PENNWALT	EQ 30MG BASE		N11613 002
	PHENTERMINE RESIN 30			
AB	QUANTUM PHARMCS	EQ 30MG BASE‡		N89120 001 FEB 04, 1988

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	/PHENERGAN VC/			
/AA/	/WYETH/AYERST/LABS/	/5MG/5ML;6.25MG/5ML/		/N08664/003/ /APR/02/1984/

PIPERACETAZINE

	/TABLET;ORAL/		
	/GUIDE/		
	/DON/PHARMS/	/10MG/	/N13615/001/
	ə DON PHARMS	10MG	N13615 001
		/25MG/	/N13615/002/
	ə	25MG	N13615 002

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

	OCL		
	/3/ABBOTT/LABS/	/6GM/100ML;75MG/100ML;168MG/100ML;/ /146MG/100ML;/ /1.29GM/100ML/	/N19284/001/ /APR/30/1986/
	ABBOTT LABS	6GM/100ML;75MG/100ML;168MG/100ML; 146MG/100ML; 1.29GM/100ML	N19284 001 APR 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

	GOLYTELY		
/AA/	/DYNAPHARM/	/227.1GM/PACKET;2.82GM/PACKET;/ /6.36GM/PACKET;5.53GM/PACKET;/ /21.5GM/PACKET/	/N71320/001/ /APR/20/1988/

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

	COLOVAGE		
AA	DYNAPHARM	227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET	N71320 001 APR 20, 1988
	COLYTE		
AB	REED & CARNRICK	227.1GM/PACKET;2.82GM/PACKET; 6.36GM/PACKET;5.53GM/PACKET; 21.5GM/PACKET‡	N18983 004 OCT 26, 1984

> ADD > **POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE**

> ADD > SOLUTION/DROPS; OPHTHALMIC
> ADD > POLYTRIM
> ADD > BURROUGHS WELLC — 10,000 UNITS/ML; EQ 1MG BASE/ML‡ — N50567 001
> ADD > OCT 20, 1988

POTASSIUM AMINOSALICYLATE

> DLT >	/POWDER;ORAL/			
> DLT >	/POTASSIUM AMINOSALICYLATE/			
> DLT >	/HEXCEL CHEM/	/100%/		/N80098/001/
> ADD >	ə HEXCEL CHEM	100%		N80098 001

POTASSIUM CHLORIDE

CAPSULE, CONTROLLED RELEASE; ORAL

	MICRO-K 10			
AB	ROBINS	10MEQ		N18238 002 MAY 14, 1984
/BC/		/10MEQ/		/N18238/002/ /MAY/14/1984/
	POTASSIUM CHLORIDE			
AB	KV PHARM	10MEQ		N70980 001 FEB 17, 1987
/BC/		/10MEQ/		/N70980/001/ /FEB/17/1987/

GRANULE FOR RECONSTITUTION, CR; ORAL

	MICRO-K LS		
	ROBINS	20MEQ/PACKET‡	N19561 003 AUG 26, 1988

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

AP	STERIS LABS	2MEQ/ML¤	N89163 001	MAR 10, 1988

TABLET, CONTROLLED RELEASE; ORAL
POTASSIUM CHLORIDE

BC	ABBOTT LABS	8MEQ¤	N18279 002	AUG 01, 1988

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

> ADD >		POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN		
> ADD >		PLASTIC CONTAINER		
> ADD >	AP	ABBOTT LABS	149MG/100ML;	
> ADD >			900MG/100ML¤	N19686 001
> ADD >				OCT 17, 1988
> ADD >		POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN		
> ADD >		PLASTIC CONTAINER		
> ADD >	AP	ABBOTT LABS	298MG/100ML;	
> ADD >			900MG/100ML¤	N19686 002
> ADD >				OCT 17, 1988

POTASSIUM CITRATE

> ADD >		POWDER FOR RECONSTITUTION; ORAL		
> ADD >		POTASSIUM CITRATE		
> ADD >		UNIV TEXAS	10MEQ/PACKET¤	N19647 002
> ADD >				OCT 13, 1988
> ADD >			20MEQ/PACKET¤	N19647 001
> ADD >				OCT 13, 1988

TABLET, CONTROLLED RELEASE; ORAL

> ADD >		POTASSIUM CITRATE		
> ADD >		UNIV TEXAS	5MEQ	N19071 001
> ADD >				AUG 30, 1985
> DLT >		/UROCIT-K/		
> DLT >		/UNIV/TEXAS/	/5MEQ/	/N19071/001/
> DLT >				/AUG/30,/1985/

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
MINIPRESS

AB	PFIZER LABS	1MG	N17442 002	
AB		2MG	N17442 003	
AB		5MG	N17442 001	

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
PRAZOSIN HCL

AB	ZENITH LABS	1MG¤	N71994 001	MAY 16, 1989 : SEP 12, 1988
AB		2MG¤	N71995 001	MAY 16, 1989 : SEP 12, 1988
AB		5MG¤	N71745 001	MAY 16, 1989 : SEP 12, 1988

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE

/BX/	/BARR/LABS/	/5MG/	/N84426/002/	
	∂ BARR LABS	5MG	N84426 002	
	/STERANE/			
/BX/	/PFIPHARMECS/	/5MG/	/N09996/001/	
	∂ PFIZER LABS	5MG	N09996 001	

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
VASOCIDIN

	IOLAB PHARMS	EQ 0.23% PHOSPHATE;10%¤	N18988 001	AUG 26, 1988

PREDNISONE

SOLUTION; ORAL
PREDNISONE

AA	MY K LABS	5MG/5ML¤	N89726 001	AUG 02, 1988
AA	ROXANE LABS	5MG/5ML	N88703 001	NOV 08, 1984

PREDNISONE

TABLET; ORAL
PREDNISONE

AB	SUPERPHARM	5MG	N88865 001 OCT 25, 1984
AB		10MG	N88866 001 OCT 25, 1984
AB		20MG	N88867 001 OCT 25, 1984
/BX/		/5MG/	/N88865/001/ /Oct/25,/1984/
/BX/		/10MG/	/N88866/001/ /Oct/25,/1984/
/BX/		/20MG/	/N88867/001/ /Oct/25,/1984/

PROBUCOL

TABLET; ORAL
LORELCO

	MERRELL DOW	500MG[M]	N17535 002 JUL 06, 1988

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL
PROCAINAMIDE HCL

>DLT >/AA/	/LEDERLE LABS/	/250MG/	/N86942/001/
>DLT >/AA/		/375MG/	/N86952/001/
>DLT >/AA/		/500MG/	/N86943/001/
>ADD >	ə LEDERLE LABS	250MG	N86942 001
>ADD >	ə	375MG	N86952 001
>ADD >	ə	500MG	N86943 001

INJECTABLE; INJECTION
PROCAINAMIDE HCL

AP	NARNER CHILCOTT	100MG/ML[M]	N89528 001 MAY 03, 1988
AP		500MG/ML[M]	N89529 001 MAY 03, 1988

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP	ELKINS SINN	EQ 5MG BASE/ML[M]	N89523 001 MAY 03, 1988

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP	QUAD PHARMS	EQ 5MG BASE/ML[M]	N89637 001 FEB 01, 1988
AP		EQ 5MG BASE/ML[M]	N89638 001 FEB 01, 1988
AP	STERLING DRUG	EQ 5MG BASE/ML[M]	N89703 001 APR 07, 1988

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

AP	MARSAM PHARMS	25MG/ML[M]	N89463 001 MAY 02, 1988
AP		50MG/ML[M]	N89477 001 MAY 02, 1988

TABLET; ORAL
PROMETHAZINE HCL

/BP/	/BARR LABS/	/12.5MG/	/N84555/001/
/BP/		/25MG/	/N84554/001/
/BP/		/50MG/	/N84557/001/
	ə BARR LABS	12.5MG	N84555 001
	ə	25MG	N84554 001
	ə	50MG	N84557 001

PROPIOLACTONE

SOLUTION; IRRIGATION
BETAPRONE

	FOREST LABS	N/A[M]	N11657 001

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HCL

/AA/	/BANMAX PHARMS/	/65MG/	/N83184/001/
	ə BANMAX PHARMS	65MG	N83184 001
/AA/	/BARR LABS/	/65MG/	/N83186/001/
	ə BARR LABS	65MG	N83186 001

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL

AB	INVAMED	10MG	N71658 001 JUL 05, 1988
AB		20MG	N71687 001 JUL 05, 1988
AB		40MG	N71688 001 JUL 05, 1988
AB		60MG	N72197 001 JUL 05, 1988
AB		80MG	N71689 001 JUL 05, 1988
AB		90MG	N72198 001 JUL 05, 1988
AB	LEDERLE LABS	10MG	N72117 001 JUN 23, 1988
AB		20MG	N72118 001 JUN 23, 1988
AB		40MG	N72119 001 JUN 23, 1988
AB		80MG	N72120 001 JUN 23, 1988
/AB/	/LEMMON/	/10MG/	/N70232/001/ /OCT/07,/1987/
	∂ LEMMON	10MG	N70232 001 OCT 07, 1987
/AB/	/PARKE/DAVIS/	/10MG/	/N70438/001/ /SEP/15,/1986/
AB	SIDMAK LABS	10MG	N71972 001 APR 06, 1988
AB		20MG	N71973 001 APR 06, 1988
AB		40MG	N71974 001 APR 06, 1988
AB		60MG	N71975 001 APR 06, 1988
AB		80MG	N71976 001 APR 06, 1988
AB		90MG	N71977 001 APR 06, 1988
AB	SUPERPHARM	10MG	N71515 001 JUN 08, 1988
AB		20MG	N71516 001 JUN 08, 1988
AB		40MG	N71517 001 JUN 08, 1988
AB		80MG	N71518 001 JUN 08, 1988
AB	WARNER CHILCOTT	10MG	N70438 001 SEP 15, 1986

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL

AB	ZENITH LABS	10MG	N72063 001 JUL 29, 1988
AB		20MG	N72066 001 JUL 29, 1988
AB		40MG	N72067 001 JUL 29, 1988
AB		60MG	N72068 001 JUL 29, 1988
AB		80MG	N72069 001 JUL 29, 1988

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

/AP/	/UPJOHN/	/50MG/VIAL/	/N07413/001/
/AP/		/250MG/VIAL/	/N07413/002/ /AUG/02,/1984/
	∂ UPJOHN	50MG/VIAL	N07413 001
	∂	250MG/VIAL	N07413 002 AUG 02, 1984

QUINESTROL

/TABLET;/ORAL/ /ESTROVIS/			
	/PARKE/DAVIS/	/0.1MG/	/N16768/002/
	∂ PARKE DAVIS	0.1MG	N16768 002
		/0.2MG/	/N16768/003/
	∂	0.2MG	N16768 003

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

AB	CORD LABS	300MG	N89839 001 SEP 29, 1988

RAUWOLFIA SERPENTINA

TABLET; ORAL
RAUVAL
BP VALE CHEM 50MG N09108 002
/B/ /100MG/ /N09108/004/
BP 100MG N09108 004
/B/ /50MG/ /N09108/002/

RESERPINE

TABLET; ORAL
RESERPINE
/BP/ /BARR/LABS/ /0.25MG/ /N80721/002/
∂ BARR LABS 0.25MG N80721 002

RESERPINE; TRICHLORMETHIAZIDE

/TABLET;ORAL/
/TRICHLORMETHIAZIDE/W//RESERPINE/
/BP/ /BOLAR/PHARM/ /0.1MG;4MG/ /N85248/001/
∂ BOLAR PHARM 0.1MG;4MG N85248 001

SECOBARBITAL SODIUM

CAPSULE; ORAL
SODIUM SECOBARBITAL
/AA/ /BARR/LABS/ /100MG/ /N84225/001/
∂ BARR LABS 100MG N84225 001

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL
BAROS
LAFAYETTE 460MG/GM;420MG/GM N18509 001
AUG 07, 1985
/MALLINCKRODT/ /460MG/GM;420MG/GM/ /N18509/001/
/AUG/07/1985/

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP KENDALL MCGAW 900MG/100ML N19635 002
MAR 09, 1988

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP ABBOTT LABS 450MG/100ML N19759 001
JUN 08, 1988

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP KENDALL MCGAW 450MG/100ML N19635 001
MAR 09, 1988

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
>ADD> AP ABBOTT LABS 9MG/ML N19217 001
>ADD> JUL 13, 1984
>DLT> /S/ /9MG/ML/ /N19217/001/
>DLT> /JUL/13/1984/

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER
AP KENDALL MCGAW 3GM/100ML N19635 003
MAR 09, 1988
AP TRAVENOL LABS 3GM/100ML N19022 001
NOV 01, 1983

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER
AP KENDALL MCGAW 5GM/100ML N19635 004
MAR 09, 1988
AP TRAVENOL LABS 5GM/100ML N19022 002
NOV 01, 1983

SODIUM IODIDE, I-131

CAPSULE; ORAL
SODIUM IODIDE I 131
>DLT> /MALLINCKRODT/ /0.8-100MCI/ /N16515/002/
>ADD> ∂ MALLINCKRODT 0.8-100MCI N16515 002

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NITROPRESS
ABBOTT LABS 25MG/ML N71961 001
AUG 01, 1988

SODIUM SUCCINATE

/INJECTABLE;INJECTION/
/SODIUM/SUCCINATE/
/ELKINS/SINN/ /30%/ /N80516/001/
∂ ELKINS SINN 30% N80516 001

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE
/AA/ /LEDERLE/LABS/ /25MG/ /N87634/001/
∂ LEDERLE LABS 25MG N87634 001

50

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM

>ADD>	AT	STERIS LABS	10%*	N89560 001 OCT 18, 1988
>ADD>				

SULFAMETHOXAZOLE

TABLET; ORAL
SULFAMETHOXAZOLE

		BARR LABS	500MG	N87189 001 JUL 25, 1983

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
TRIMETH/SULFA

AB	NASKA PHARMA	200MG/5ML;40MG/5ML*	N72289 001 MAY 23, 1988
AB		200MG/5ML;40MG/5ML*	N72398 001 MAY 23, 1988
AB		200MG/5ML;40MG/5ML*	N72399 001 MAY 23, 1988

SULFISOXAZOLE

TABLET; ORAL
SULFISOXAZOLE

	BARR LABS	500MG	N84031 001
	LEDERLE LABS	500MG	N87649 001

SULINDAC

TABLET; ORAL
CLINORIL

AB	MS&D	150MG	N17911 001
AB		200MG	N17911 002

SULINDAC

AB	AM THERPTCS	150MG*	N72171 001 MAY 23, 1988
AB		200MG*	N72172 001 MAY 23, 1988

SULINDAC

TABLET; ORAL
SULINDAC

AB	DANBURY PHARMA	150MG*	N71891 001 APR 03, 1990 : MAR 03, 1988
AB		200MG*	N71795 001 APR 03, 1990 : MAR 03, 1988

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE; INJECTION
OSTEOSCAN

	MEDI PHYSICS	N/A	N17667 001
	MALLINCKRODT	N/A	N17454 001

TEMAZEPAM

CAPSULE; ORAL
TEMAZEPAM

AB	CORD LABS	15MG*	N71427 001 JAN 12, 1988
AB		30MG*	N71428 001 JAN 12, 1988
AB	DURAMED PHARMS	15MG*	N71708 001 SEP 29, 1988
AB		30MG*	N71709 001 SEP 29, 1988

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL
HYTRIN

	ABBOTT LABS	10MG	N19057 004 AUG 07, 1987

TERCONAZOLE

SUPPOSITORY; VAGINAL
TERAZOL 3

	ORTHO PHARM	80MG*	N19641 001 MAY 24, 1988

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION
TESTOSTERONE CYPIONATE

>ADD>	AQ	QUAD PHARMS	100MG/ML*		N89326 001 OCT 28, 1988
>ADD>	AQ		200MG/ML*		N89327 001 OCT 28, 1988

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL

AB	LABROS ATRAL	250MG*		N62752 001 AUG 12, 1988
AB		500MG*		N62752 002 AUG 12, 1988
AB	VITARINE	250MG		N61471 001

THEOPHYLLINE

ELIXIR; ORAL
THEOPHYLLINE

AA	NASKA PHARMA	80MG/15ML*		N89223 001 MAY 27, 1988
>ADD> AA	THAMES PHARMA	80MG/15ML*		N89626 001 OCT 28, 1988

INJECTABLE; INJECTION
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	TRAVENOL LABS	320MG/100ML	N18649 006 NOV 13, 1985

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT LABS	320MG/100ML*	N19211 006 JAN 20, 1988

TABLET, CONTROLLED RELEASE; ORAL
THEOLAIR-SR

BC	RIKER LABS	250MG		N86363 002 JUL 16, 1987
		/250MG/		/N86363/002/ /JUL/16,/1987/

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL
THIORIDAZINE HCL

>ADD> AB	MUTUAL PHARM	100MG*		N89953 001 OCT 07, 1988

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL
THIORIDAZINE HCL

AB	PAR PHARM	150MG*		N89764 001 FEB 09, 1988
AB		200MG*		N89765 001 FEB 09, 1988
AB	ROXANE LABS	25MG		N88664 001 MAR 15, 1984

TIOCONAZOLE

	/OINTMENT;VAGINAL/ /VAGISTAT/ /ROERIG/	/6.5%/		/N19355/001/ /DEC/30,/1986/
	∂ ROERIG	6.5%		N19355 001 DEC 30, 1986

TIOPRONIN

TABLET; ORAL
TIOPRONIN

	UNIV TEXAS	100MG*		N19569 001 AUG 11, 1988

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

AB	PHARM BASICS	100MG*		N71355 001 JAN 11, 1988

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE

/AB/	/BANMAX/PHARMS/	/500MG/		/N86141/001/
	∂ BANMAX PHARMS	500MG		N86141 001

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
DESYREL

AB	MEAD JOHNSON	150MG		N18207 003 MAR 25, 1985

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HCL

AB	PUREPAC PHARM	50MG	N71636 001 APR 18, 1988
AB		100MG	N71514 001 APR 18, 1988
AB	SIDMAK LABS	50MG	N71523 001 DEC 11, 1987
AB		100MG	N71524 001 DEC 11, 1987
/AB/	/TRAZON-100/ /SIDMAK/LABS/	/100MG/	/N71524/001/ /DEC/11,/1987/

† TRAZON-150

AB	SIDMAK LABS	150MG	N71525 001 MAR 09, 1988
/AB/	/TRAZON-50/ /SIDMAK/LABS/	/50MG/	/N71523/001/ /DEC/11,/1987/

TRETINOIN

CREAM; TOPICAL

RETIN-A

	ORTHO PHARM	0.025%	N19049 001 SEP 16, 1988

TRIAMCINOLONE

TABLET; ORAL

TRIAMCINOLONE

/BP/	/BARR/LABS/	/2MG/	[illegible]
/BP/		/2MG/	
/BP/		/4MG/	
/BP/		/4MG/	
/BP/		/8MG/	
/BP/		/8MG/	
	∂ BARR LABS	2MG	N84286 001
	∂	2MG	N84318 001
	∂	4MG	N84267 001
	∂	4MG	N84319 001
	∂	8MG	N84268 001
	∂	8MG	N84320 001

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRYMEX

/AT/	/SAVAGE/LABS/	/0.5%/	/N88198/001/ /MAR/25,/1983/
	∂ SAVAGE LABS	0.5%	N88198 001 MAR 25, 1983

TRIAZOLAM

TABLET; ORAL

HALCION

	/UPJOHN/	/0.5MG/	/N17892/002/ /NOV/15,/1982/
	∂ UPJOHN	0.5MG	N17892 002 NOV 15, 1982

TRICLOFOS SODIUM

SOLUTION; ORAL

TRICLOS

	/MERRELL/DON/	/1.5GM/15ML/	/N16830/001/
	∂ MERRELL DON	1.5GM/15ML	N16830 001

/TABLET;/ORAL/

/TRICLOS/

	/MERRELL/DON/	/750MG/	/N16809/002/
	∂ MERRELL DON	750MG	N16809 002

TRIDIHEXETHYL CHLORIDE

/INJECTABLE;/INJECTION/

/PATHILON/

	/LEDERLE/LABS/	/10MG/ML/	/N09729/001/
	∂ LEDERLE LABS	10MG/ML	N09729 001

TRIFLUOPERAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

STELAZINE

>ADD > AP	SK&F CO	EQ 2MG BASE/ML	N11552 005

>ADD >

TRIFLUOPERAZINE HCL

>ADD > AP	QUAD PHARMS	EQ 2MG BASE/ML	N89893 001 OCT 17, 1988

>ADD >

† SEE SECTION 1.4 OF INTRODUCTION

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL

AB	BOLAR PHARM	EQ 1MG BASE*	N85975 001	JUN 23, 1988
AB		EQ 2MG BASE*	N85976 001	JUN 23, 1988
AB		EQ 5MG BASE*	N85973 001	JUN 23, 1988
AB		EQ 10MG BASE*	N88710 001	JUN 23, 1988

TRIMEPRAZINE TARTRATE

CAPSULE, CONTROLLED RELEASE; ORAL
TEMARIL

>ADD>	HERBERT LABS	EQ 5MG BASE	N11316 004	
>DLT>	/SKAF/LABS/	/EQ/5MG/BASE/	/N11316/004/	

SYRUP; ORAL
TEMARIL

>ADD> AA	HERBERT LABS	EQ 2.5MG BASE/5ML	N11316 003	
>DLT>/AA/	/SKAF/LABS/	/EQ 2.5MG BASE/5ML/	/N11316/003/	

TABLET; ORAL
TEMARIL

>ADD>	HERBERT LABS	EQ 2.5MG BASE	N11316 001	
>DLT>	/SKAF/LABS/	/EQ/2.5MG/BASE/	/N11316/001/	

TRIMETHOPRIM

TABLET; ORAL
TRIMETHOPRIM

AB	BARR LABS	100MG	N70494 001	JAN 22, 1986
/AB/		/200MG/	/N70495/001/	/MAR/14,/1986/
/S/		/100MG/	/N70494/001/	/JAN/22,/1986/
∂		200MG	N70495 001	MAR 14, 1986

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL
TRIPELENNAMINE HCL

/AB/	/BARR/LABS/	/50MG/	/N80744/001/	
∂	BARR LABS	50MG	N80744 001	

TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
>DLT> /MYLOL/
>DLT>/AA/ /MY/K/LABS/ /1.25MG/5ML/ /N87963/001/ /JAN/18,/1983/
>DLT>
>ADD> ∂ MY K LABS 1.25MG/5ML N87963 001 JAN 18, 1983
>ADD>

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE

AP	QUAD PHARMS	3MG/ML*	N89442 001	AUG 12, 1988

URSODIOL

CAPSULE; ORAL
ACTIGALL

∂ CIBA PHARM	150MG	N19594 001	DEC 31, 1987
	300MG	N19594 002	DEC 31, 1987
/DEURSIL/			
/SIPHARMEX/	/150MG/	/N19594/001/	/DEC/31,/1987/
	/300MG/	/N19594/002/	/DEC/31,/1987/

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
LYPHOCIN

AP	LYPHOMED	EQ 1GM BASE/VIAL	N62663 002	JUL 31, 1987
AP		EQ 5GM BASE/VIAL*	N62663 003	JUN 03, 1988

VANCOCIN HCL

AP	LILLY	EQ 1GM BASE/VIAL	N60180 002	MAR 21, 1986
AP		EQ 1GM BASE/VIAL	N62476 002	MAR 21, 1986
AP		EQ 1GM BASE/VIAL	N62716 002	MAR 13, 1987
AP		EQ 1GM BASE/VIAL	N62812 002	NOV 17, 1987
AP		EQ 10GM BASE/VIAL	N62812 003	NOV 17, 1987

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOLED

AP	LEDERLE LABS	EQ 1GM BASE/VIAL*	N62682 002 MAR 30, 1988
AP		EQ 5GM BASE/VIAL	N62682 004 MAY 11, 1988
AP		EQ 10GM BASE/VIAL*	N62682 005 MAY 11, 1988
		EQ 2GM BASE/VIAL*	N62682 003 MAY 11, 1988

VANCOMYCIN HCL

AP	ABBOTT LABS	EQ 500MG BASE/VIAL*	N62911 001 AUG 04, 1988
AP		EQ 1GM BASE/VIAL*	N62912 001 AUG 04, 1988
AP	ELKINS SINN	EQ 500MG BASE/VIAL*	N62879 001 AUG 02, 1988
AP		EQ 1GM BASE/VIAL*	N62879 002 AUG 02, 1988
AP	QUAD PHARMS	EQ 500MG BASE/VIAL*	N62845 001 JUL 15, 1988
AP		EQ 1GM BASE/VIAL*	N62845 002 JUL 15, 1988

VANCOR

AP	ADRIA LABS	EQ 500MG BASE/VIAL*	N62956 001 AUG 01, 1988
AP		EQ 1GM BASE/VIAL*	N62956 002 AUG 01, 1988

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

CALAN

AB	SEARLE PHARMS	40MG*	N18817 003 FEB 23, 1988
a		160MG	N18817 004 FEB 23, 1988

ISOPTIN

AB	KNOLL PHARM	40MG	N18593 003 NOV 23, 1987

VERAPAMIL HCL

AB	CORD LABS	80MG*	N71423 001 MAY 24, 1988
AB		120MG*	N71424 001 MAY 25, 1988

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

VERAPAMIL HCL

AB	LEDERLE LABS	80MG*	N71880 001 APR 05, 1988
AB		120MG*	N71881 001 APR 05, 1988
AB	MUTUAL PHARM	80MG*	N71488 001 JAN 13, 1988
AB		120MG*	N71489 001 JAN 13, 1988

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCREX

AP	BRISTOL LABS	5MG/VIAL*	N70867 001 JUL 12, 1988

VINCRISTINE SULFATE

AP	BULL LABS	1MG/VIAL*	N71559 001 APR 11, 1988
AP		2MG/VIAL*	N71560 001 APR 11, 1988
AP		5MG/VIAL*	N71561 001 APR 11, 1988
AP	QUAD PHARMS	1MG/VIAL	N71222 001 MAR 07, 1988
AP		2MG/VIAL	N71223 001 MAR 07, 1988
AP		5MG/VIAL	N71937 001 MAR 07, 1988

VINCRISTINE SULFATE PFS

AP	BULL LABS	1MG/ML*	N71484 001 APR 19, 1988

WATER FOR INJECTION, STERILE

LIQUID; N/A

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	BAXTER	100%*	N18632 002 APR 19, 1988
AP	KENDALL MCGAW	100%*	N19633 001 FEB 29, 1988

XYLOSE

POWDER; ORAL

a	LYNE LABS	25GM/BOT	N18856 001 MAR 26, 1987

ACETAMINOPHEN

SUPPOSITORY; RECTAL

	NEOPAP			
> DLT >	/REBCON/PHARMS/	/120MG/		/N16401/001/
> ADD >	ALCON LABS	120MG		N16401 001
	TYLENOL			
	MCNEIL CONSUMER	120MG		N17756 002
		650MG		N17756 001
	/MCNEIL/LABS/	/120MG/		/N17756/002/
		/650MG/		/N17756/001/

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE

/TABLET;/CONTROLLED/RELEASE;/ORAL/

/BROMATAPP/			
/COPLEY/PHARM/	/12MG;75MG/		/N71099/001/
			/JUL/02;/1987/

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, CONTROLLED RELEASE; ORAL

BROMATAPP			
COPLEY PHARM	12MG;75MG		N71099 001
			JUL 02, 1987

BUTYL METHOXYDIBENZOYLMETHANE; PADIMATE O

LOTION; TOPICAL

PHOTOPLEX			
HERBERT LABS	3%;7%*		N19459 001
			SEP 30, 1988

CHLORPHENIRAMINE MALEATE

CAPSULE, CONTROLLED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE			
CORD LABS	12MG*		N70797 001
			AUG 12, 1988

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, CONTROLLED RELEASE; ORAL

PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE			
CENTRAL PHARMS	8MG;120MG*		N19428 001
			AUG 02, 1988

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, CONTROLLED RELEASE; ORAL

RESPORAL			
PIONEER PHARMS	6MG;120MG*		N89139 001
			JUN 16, 1988

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN DM			
WYETH AYERST LABS	15MG/5ML;6.25MG/5ML*		N11265 003
			AUG 11, 1988

HYDROCORTISONE

OINTMENT; TOPICAL

HC (HYDROCORTISONE)			
C&M PHARMA	0.5%		N80481 001

IBUPROFEN

TABLET; ORAL

IBU-TAB 200			
ALRA LABS	200MG*		N71057 001
			AUG 11, 1988
IBUPROFEN			
DANBURY PHARMA	200MG*		N71905 001
			MAR 08, 1988
INTERPHARM	200MG*		N72199 001
			MAY 23, 1988
INVAMED	200MG*		N71807 001
			FEB 25, 1988
MEDICOPHARMA	200MG*		N71639 001
			FEB 02, 1988
MYLAN PHARMS	200MG*		N71870 001
			MAY 05, 1988
PRIVATE FMLTNS	200MG*		N72299 001
			JUL 01, 1988
ZENITH LABS	200MG*		N72040 001
			APR 29, 1988
NUPRIN			
BRISTOL MYERS	200MG*		N72035 001
			FEB 16, 1988
	200MG*		N72036 001
			FEB 16, 1988

INJECTABLE; INJECTION
MIXTARD HUMAN 70/30
NORDISK USA — 30 UNITS/ML; 70 UNITS/ML — N19585 001 — MAR 11, 1988

INSULIN ZINC SUSP EXTENDED BIOSYNTHETIC HUMAN

INJECTABLE; INJECTION
HUMULIN U
/LILLY/ — /40/UNITS/ML/ — /N19571/001/ /JUN/10,/1987/
LILLY — 40 UNITS/ML — N19571 001 — JUN 10, 1987

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
IMODIUM A-D
MCNEIL CONSUMER — 1MG/5ML — N19487 001 — MAR 01, 1988

NONOXYNOL-9

SPONGE; VAGINAL
TODAY
/LI/ — /1GM/ — /N18683/001/ /APR/01,/1983/
WHITEHALL LABS — 1GM — N18683 001 — APR 01, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION
OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION

TERUMO	0.9GM/100ML;0.877GM/100ML; 0.525GM/100ML;0.03GM/100ML	N 880217 OCT 07, 1988

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
MACRODEX(R)

PHARMACIA INC	6GM/100ML;0.9GM/100ML	N 06826

~~PROPIOLACTONE 99%~~
~~SOLUTION; CHEMICAL STERILIZING AGENT~~
~~BETAPRONE~~

~~ONEAL JONES&FELDMAN~~	~~99GM/100ML~~	~~N 11657~~

ORPHAN DRUG PRODUCTS WITH EXCLUSIVE APPROVAL

SECTION 526 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT CONTAINS PROVISIONS WHEREBY FDA MAY DESIGNATE A SPONSOR'S DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT AS A "DESIGNATED ORPHAN DRUG". SECTION 527 OF THE ACT ESTABLISHES A PROCESS WHEREBY A SPONSOR MAY RECEIVE SEVEN YEARS OF EXCLUSIVE APPROVAL STATUS IF THAT SPONSOR IS THE FIRST TO ACHIEVE NEW DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT APPROVAL FOR A DESIGNATED ORPHAN DRUG FOR THE DESIGNATED INDICATION(S). THE EXCLUSIVE APPROVAL MAY BE REVOKED BY WRITTEN CONSENT OF THE SPONSOR OR BY FDA ACTION AFTER FINDING THAT THE SPONSOR HOLDING EXCLUSIVE APPROVAL CANNOT ASSURE THE AVAILABILITY OF SUFFICIENT QUANTITIES OF THE DRUG TO MEET THE NEEDS OF PATIENTS WITH THE DESIGNATED ORPHAN INDICATION(S).

ORPHAN DRUG EXCLUSIVE APPROVAL STATUS (CODED ODE) APPLIES ONLY TO THE APPROVED OR LICENSED INDICATION(S) FOR WHICH ORPHAN DRUG DESIGNATION HAS BEEN GRANTED PURSUANT TO SECTION 526 OF THE ACT.

FOR THE FOLLOWING DRUG PRODUCTS WITH ORPHAN DRUG EXCLUSIVE APPROVAL STATUS, THE SPONSOR HAS SEVEN YEARS OF EXCLUSIVE APPROVAL FOR THE APPROVED INDICATION BEGINNING ON THE DATE OF NDA, ANTIBIOTIC APPLICATION, OR BIOLOGICAL LICENSE APPROVAL FOR THE DRUG. NO SUBSEQUENT SPONSOR MAY RECEIVE APPROVAL OF AN NDA, BIOLOGICAL LICENSE, PAPER NDA, ANTIBIOTIC APPLICATION, ANDA, OR ABBREVIATED ANTIBIOTIC APPLICATION DURING THE SEVEN YEAR PERIOD FOR THE DRUG AND INDICATION(S) FOR WHICH ODE STATUS IS MAINTAINED UNLESS THE EXCLUSIVE APPROVAL HAS BEEN REVOKED AS DESCRIBED ABOVE OR THE SUBSEQUENT SPONSOR HAS OBTAINED WRITTEN CONSENT FROM THE SPONSOR WHO HAS RECEIVED EXCLUSIVE APPROVAL.

BIOLOGICAL PRODUCTS, ANTIBIOTICS, AND DRUGS THAT HAVE BEEN APPROVED UNDER SECTION 505 OR 507 OF THE ACT OR UNDER SECTION 351 OF THE PUBLIC HEALTH SERVICE ACT FOR MARKETING AND HAVE BEEN GIVEN ORPHAN DRUG EXCLUSIVE APPROVAL WILL BE NOTED BY THE ABBREVIATION ODE IN THE PATENT AND EXCLUSIVITY INFORMATION ADDENDUM. DRUG PRODUCTS THAT HAVE RECEIVED THE WRITTEN PERMISSION OF THE SPONSOR THAT HAS ORPHAN DRUG EXCLUSIVE APPROVAL TO BE APPROVED UNDER SECTION 527(b)(2) OF THE ACT ARE ALSO NOTED BY THE ABBREVIATION ODE IN THE PATENT AND EXCLUSIVITY INFORMATION ADDENDUM. THESE DRUG PRODUCTS DO NOT HAVE ANY EXCLUSIVE APPROVAL RIGHTS OF THEIR OWN, BUT CAN BE MARKETED BECAUSE OF THE CONSENT GIVEN BY THE SPONSOR THAT HAS EXCLUSIVE APPROVAL. THESE PRODUCTS ARE MARKED BY AN (*) NEXT TO THE APPLICANT'S NAME.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 8TH EDITION FOR A FULL LISTING OF ORPHAN DRUG PRODUCTS WITH EXCLUSIVE APPROVAL DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ORPHAN DRUG PRODUCTS WITH EXCLUSIVE APPROVAL

DRUG PRODUCTS

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME DOSAGE FORM; ROUTE	APPLICANT	APPL. PROD. APPROVAL DATE	EXCLUSIVITY EXP. DATE
LEUCOVORIN CALCIUM EQ 3MG BASE/ML	LEUCOVORIN CALCIUM INJECTABLE; INJECTION	LEDERLE LABS	08107 001 AUG 31, 1988	ODE[1] AUG 31, 1995
LEUCOVORIN CALCIUM EQ 50MG BASE/VIAL	LEUCOVORIN CALCIUM INJECTABLE; INJECTION	LEDERLE LABS	08107 002 AUG 31, 1988	ODE[1] AUG 31, 1995
LEUCOVORIN CALCIUM EQ 100MG BASE/VIAL	LEUCOVORIN CALCIUM INJECTABLE; INJECTION	LEDERLE LABS	08107 004 AUG 31, 1988	ODE[1] AUG 31, 1995
LEUCOVORIN CALCIUM EQ 60MG BASE/VIAL	LEUCOVORIN CALCIUM POWDER FOR RECONSTITUTION; ORAL	LEDERLE LABS	08107 003 AUG 31, 1988	ODE[1] AUG 31, 1995
METHOTREXATE SODIUM EQ 20MG BASE/VIAL	METHOTREXATE INJECTABLE; INJECTION	LEDERLE LABS	11719 001 APR 07, 1988	ODE[2] APR 07, 1995

[1]ODE PERTAINS ONLY TO INDICATION I-79 (SEE EXCLUSIVITY TERMS)
[2]ODE PERTAINS ONLY TO INDICATION I-78 (SEE EXCLUSIVITY TERMS)

ORPHAN DRUG PRODUCTS WITH EXCLUSIVE APPROVAL

DRUG PRODUCTS

ACTIVE INGREDIENT(S) STRENGTH(S)	TRADE NAME DOSAGE FORM; ROUTE	APPLICANT	APPL. PROD. APPROVAL DATE	EXCLUSIVITY EXP. DATE
METHOTREXATE SODIUM EQ 50MG BASE/VIAL	METHOTREXATE INJECTABLE; INJECTION	LEDERLE LABS	11719 003 APR 07, 1988	ODE[2] APR 07, 1995
METHOTREXATE SODIUM EQ 100MG BASE/VIAL	METHOTREXATE INJECTABLE; INJECTION	LEDERLE LABS	11719 006 APR 07, 1988	ODE[2] APR 07, 1995
METHOTREXATE SODIUM EQ 1GM BASE/VIAL	METHOTREXATE INJECTABLE; INJECTION	LEDERLE LABS	11719 009 APR 07, 1988	ODE[2] APR 07, 1995
METHOTREXATE SODIUM EQ 25MG BASE/ML	METHOTREXATE LPF INJECTABLE; INJECTION	LEDERLE LABS	11719 007 APR 07, 1988	ODE[2] APR 07, 1995
POTASSIUM CHLORIDE 10MEQ/PACKET	POTASSIUM CHLORIDE POWDER, FOR RECONSTITUTION	UNIV TEXAS	19647 002 OCT 13, 1988	ODE[2] AUG 30, 1992
POTASSIUM CHLORIDE 20MEQ/PACKET	POTASSIUM CHLORIDE POWDER, FOR RECONSTITUTION	UNIV TEXAS	19647 001 OCT 13, 1988	ODE[2] AUG 30, 1992
TIOPRONIN 100MG	TIOPRONIN TABLET; ORAL	UNIV TEXAS	19569 001 AUG 11, 1988	ODE AUG 11, 1995

[2]ODE PERTAINS ONLY TO INDICATION I-78 (SEE EXCLUSIVITY TERMS)

DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO OCTOBER 1988 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR IN VIVO BIOEQUIVALENCE STUDIES AND IN VITRO DISSOLUTION TESTING AVAILABLE FROM THE DIVISION OF BIOEQUIVALENCE, HFN-250, ROOM 17B-06, 5600 FISHERS LANE, ROCKVILLE, MD 20857. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 8TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
ACETOHEXAMIDE (TABLET)	NOV 15, 1985	AUG 01, 1988
ALBUTEROL; METAPROTERENOL SULFATE (METERED DOSE INHALER)	AUG 25, 1988	
AMOXAPINE (TABLET)	SEP 10, 1987	AUG 05, 1988
ATENOLOL (TABLET)	OCT 06, 1988	
CARBAMAZEPINE (TABLET)	JAN 01, 1988	
CLINDAMYCIN (CAPSULE)	MAY 31, 1988	
CONJUGATED ESTROGEN (TABLET)*	DEC 27, 1986	
CYCLOBENZAPRINE HYDROCHLORIDE (TABLET)	JAN 25, 1988	
DOXYCYCLINE HYCLATE (CAPSULE AND TABLET)	APR 11, 1988	
ERYTHROMYCIN (CAPSULE, ENTERIC COATED PELLETS)	SEP 21, 1988	
FENOPROFEN (CAPSULE AND TABLET)	AUG 27, 1987	FEB 03, 1988
INDOMETHACIN (CAPSULE)	JAN 27, 1988	
LEUCOVORIN CALCIUM (TABLET)	APR 28, 1987	AUG 04, 1988
MESTRANOL; NORETHYNODREL (TABLET)	MAY 13, 1988	
METAPROTERENOL SULFATE (TABLET)	MAR 18, 1988	
NORETHINDRONE; ETHINYL ESTRADIOL (TABLET)	MAR 18, 1988	
PRAZEPAM (CAPSULE AND TABLET)	JUL 26, 1988	
RIFAMPIN (CAPSULE)	SEP 08, 1988	
TIMOLOL MALEATE (TABLET)	AUG 09, 1988	

*THE METHODOLOGY IN THE BIOPHARMACEUTICAL AVAILABILITY GUIDANCE IS NO LONGER ACCEPTED BY THE AGENCY.

ANDA SUITABILITY PETITIONS

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 8TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ASPIRIN; HYDROCODONE BITARTRATE TABLET; ORAL	325MG 5MG	87 P-0376/ CP0002	ANABOLIC	NEW STRENGTH	APPROVED FEB 12, 1988
ASPIRIN; HYDROCODONE BITARTRATE TABLET; ORAL	650MG 5MG	87 P-0376/CP	ANABOLIC	NEW STRENGTH	APPROVED FEB 12, 1988
CHLORHEXIDINE GLUCONATE SPRAY; TOPICAL	0.5%	88 P-0036/CP	ARENT, FOX, KINTNER, PLOTKIN & KAHN	NEW DOSAGE FORM	APPROVED AUG 19, 1988
CHLORZOXAZONE CAPSULE; ORAL	500MG	82 N-0032/ CP0006	MIKART	NEW DOSAGE FORM	APPROVED JAN 13, 1988

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
CISPLATIN INJECTABLE; INJECTION	1MG/ML (10ML/VIAL) (50ML/VIAL) (100ML/VIAL)	87 P-0421/CP	BULL LABS	NEW DOSAGE FORM NEW STRENGTH	APPROVED FEB 29, 1988
CISPLATIN INJECTABLE; INJECTION	1MG/ML (20ML/VIAL)	88 P-0010/CP	LYPHOMED	NEW DOSAGE FORM NEW STRENGTH	APPROVED APR 01, 1988
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	20MG/ML (500ML/CONTAINER)	88 P-0011/CP	BAXTER HLTHCARE	NEW DOSAGE FORM NEW STRENGTH	APPROVED JUN 10, 1988
FLUOROURACIL INJECTABLE; INJECTION	50MG/ML (5ML/VIAL)	88 P-0052/CP	BEN VENUE LABS	NEW STRENGTH	APPROVED MAR 21, 1988
HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE SOFT GELATIN CAPSULE; ORAL	1.5MG 5MG	88 P-0061/CP	KLEINFELD, KAPLAN AND BECKER	NEW DOSAGE FORM	APPROVED MAY 12, 1988
HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML 40MG/5ML	87 P-0399/CP	BURDITT, BOWLES, RADZIUS AND RUBERRY	NEW DOSAGE FORM	APPROVED FEB 16, 1988

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML 80MG/5ML	87 P-0399/CP	BURDITT, BOWLES, RADZIUS AND RUBERRY	NEW DOSAGE FORM	APPROVED FEB 16, 1988
HYDROCHLOROTHIAZIDE; TRIAMTERENE TABLET; ORAL	25MG 50MG	87 P-0335/CP	PAR PHARM	NEW DOSAGE FORM	APPROVED FEB 26, 1988
LEUCOVORIN CALCIUM SOLUTION; ORAL	EQ 1MG BASE/ML	88 P-0149/CP	ROXANE LABS	NEW DOSAGE FORM	APPROVED JUL 25, 1988
MEPERIDINE HYDROCHLORIDE INJECTABLE; INJECTION	10MG/ML (50ML/CONTAINER)	88 P-0008/CP	LYPHOMED	NEW STRENGTH	APPROVED APR 01, 1988
METOCLOPRAMIDE HYDROCHLORIDE INTENSOL CONCENTRATE; ORAL	10MG/ML	88 P-0164/CP	ROXANE LABS	NEW STRENGTH	APPROVED JUN 28, 1988
NIFEDIPINE CAPSULE; ORAL	10MG	88 P-0072/ CP0002	MARTEC PHARMS	NEW DOSAGE FORM	APPROVED MAY 11, 1988
NIFEDIPINE CAPSULE; ORAL	20MG	88 P-0072/CP	MARTEC PHARMS	NEW DOSAGE FORM	APPROVED MAY 11, 1988

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
PHENYLPROPANOLAMINE HYDROCHLORIDE FILM, CONTROLLED RELEASE; PERCUTANEOUS	150MG	88 P-0265/CP	BIO AMERICAN	NEW DOSAGE FORM NEW STRENGTH NEW INDICATION	APPROVED OCT 07, 1988
PHENYTOIN SODIUM INJECTABLE; INJECTION	100MG/VIAL 250MG/VIAL	87 P-0367/CP	LYPHOMED	NEW DOSAGE FORM	APPROVED FEB 16, 1988
PREDNISOLONE SODIUM PHOSPHATE SOLUTION; ORAL	EQ 5MG BASE/ML	88 P-0235/CP	PAN AM PHARMS	NEW STRENGTH	APPROVED AUG 24, 1988
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER INJECTABLE; INJECTION	900MG/100ML (100ML/CONTAINER)	87 P-0391/CP	LYPHOMED	NEW STRENGTH	APPROVED AUG 11, 1988
STERILE WATER IN PLASTIC CONTAINER INJECTABLE; INJECTION	100% (100ML/CONTAINER)	87 P-0392/CP	LYPHOMED	NEW STRENGTH	APPROVED AUG 11, 1988
THEOPHYLLINE CAPSULE, CONTROLLED RELEASE; ORAL	450MG	88 P-0119/CP	RIKER LABS	NEW STRENGTH	APPROVED MAY 11, 1988

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
THEOPHYLLINE CAPSULE, CONTROLLED RELEASE; ORAL	500MG	88 P-0226/CP	SAVAGE LABS	NEW STRENGTH	APPROVED AUG 25, 1988
THIOTEPA (WITH DILUENT) INJECTABLE; INJECTION	15MG/VIAL	87 P-0382/CP	LYPHOMED	NEW DOSAGE FORM	APPROVED MAY 12, 1988
VERAPAMIL HYDROCHLORIDE CAPSULE, CONTROLLED RELEASE; ORAL	120MG 240MG	87 P-0233/CP	SEARLE	NEW DOSAGE FORM NEW STRENGTH	APPROVED FEB 26, 1988

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
BENZOYL METRONIDAZOLE SUSPENSION; ORAL	200MG/5ML	85 P-0258/CP	APKON LABS	NEW INGREDIENT (NEW ESTER)	DENIED MAR 19, 1986
BROMPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE SYRUP; ORAL	2MG/5ML 2.5MG/5ML 12.5MG/5ML	85 P-0237/CP	MIKART	NEW COMBINATION	DENIED MAY 11, 1988
BROMDIPHENHYDRAMINE HYDROCHLORIDE; HYDROCODONE BITARTRATE SOLUTION; ORAL	12.5MG/5ML 2.5MG/5ML	85 P-0255/CP	MIKART	NEW COMBINATION	DENIED MAY 11, 1988
BROMDIPHENHYDRAMINE HYDROCHLORIDE; HYDROCODONE BITARTRATE SYRUP; ORAL	12.5MG/5ML 2.5MG/5ML	85 P-0255/CP	MIKART	NEW COMBINATION	DENIED MAY 11, 1988
CYCLOBENZAPRINE HYDROCHLORIDE TABLET; ORAL	15MG	86 P-0386/CP	CENTRAL PHARMS	NEW STRENGTH	DENIED AUG 15, 1988
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	100MG/ML (1ML/VIAL) (2ML/VIAL)	87 P-0283/CP	LYPHOMED	NEW DOSAGE FORM NEW STRENGTH	DENIED JAN 21, 1988

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
CYCLOPHOSPHAMIDE INJECTABLE; INJECTION	500MG/ML (1ML/VIAL) (2ML/VIAL) (4ML/VIAL)	87 P-0283/CP	LYPHOMED	NEW DOSAGE FORM NEW STRENGTH	DENIED JAN 21, 1988
DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, SUSTAINED RELEASE; ORAL	75MG	87 P-0355/CP	PARKE DAVIS	NEW DOSAGE FORM NEW STRENGTH	DENIED MAY 11, 1988
HYDROCODONE BITARTRATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE SYRUP; ORAL	1.66MG/5ML 5MG/5ML 6.25MG/5ML	85 P-0389/CP	UAD LABS	NEW COMBINATION	DENIED MAY 11, 1988
HYDROCODONE BITARTRATE; PROMETHAZINE HYDROCHLORIDE SYRUP; ORAL	2.5MG/5ML 6.25MG/5ML	85 P-0256/CP	MiKART	NEW COMBINATION	DENIED MAY 11, 1988
MAGNESIUM ASCORBATE INJECTABLE; INJECTION	10% 20%	88 P-0200/CP	RIM CONSULTING	NEW INGREDIENT	DENIED JUN 10, 1988

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
METOCLOPRAMIDE HYDROCHLORIDE INJECTABLE; INJECTION	1MG/ML (50ML/VIAL)	87 P-0090/CP	INTL MEDTN SYS	NEW STRENGTH	DENIED FEB 08, 1988
METOCLOPRAMIDE HYDROCHLORIDE INJECTABLE; INJECTION	1MG/ML (75ML/VIAL)	87 P-0090/CP	INTL MEDTN SYS	NEW STRENGTH	DENIED FEB 08, 1988
METOCLOPRAMIDE HYDROCHLORIDE INJECTABLE; INJECTION	1MG/ML (100ML/VIAL)	87 P-0090/CP	INTL MEDTN SYS	NEW STRENGTH	DENIED FEB 08, 1988

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 8TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG

NEW INDICATION

I-19	CHOLANGIOPANCREATOGRAPHY
I-72	PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-73	FOLLICULAR STIMULATION IN IN VITRO FERTILIZATION
I-74	MANAGEMENT OF CONGESTIVE HEART FAILURE
I-75	ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-76	HERNIOGRAPHY
I-77	KNEE ARTHROGRAPHY
I-78	HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-79	RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
I-80	SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-81	TREATMENT OF RHEUMATOID ARTHRITIS

EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODE

U-26	METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
U-27	METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
U-28	METHOD FOR IMPROVING MEMORY IN MAMMALS
U-29	METHOD FOR TREATING AMNESIA
U-30	METHOD OF POTENTIATING CODEINE ANALGESIA IN MAMMALS
U-31	USE IN LUNG SCANNING PROCEDURES
U-32	TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
U-33	METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
U-34	TREATMENT OF INFLAMMATION

APPL/PROD	INGREDIENT NAME: TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19489 001	ALBUTEROL SULFATE; VENTOLIN ROTACAPS	3705233	DEC 05, 1989			
		3644353	FEB 22, 1989		NDF	MAY 04, 1991
18116 002	AMCINONIDE; CYCLOCORT	4158055	JUN 12, 1996	U-34		
18498 001	AMCINONIDE; CYCLOCORT	4158055	JUN 12, 1996	U-34		
19716 001	BETAMETHASONE DIPROPIONATE; DIPROLENE				NP	AUG 01, 1991
18644 001	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	MAR 26, 2002			
18644 002	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	MAR 26, 2002			
18644 003	BUPROPION HYDROCHLORIDE; WELLBUTRIN	4507323	MAR 26, 2002			
19459 001	BUTYL METHOXYDIBENZOYLMETHANE; PHOTOPLEX	4387089	JUN 07, 2000		NP	SEP 30, 1991
17920 002	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
		3950333	APR 13, 1993		D-12	APR 30, 1989
17920 003	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
		3950333	APR 13, 1993		D-12	APR 30, 1989
17920 004	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
		3950333	APR 13, 1993		D-12	APR 30, 1989
17920 005	CIMETIDINE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
		3950333	APR 13, 1993		D-12	APR 30, 1989
17924 001	CIMETIDINE HYDROCHLORIDE; TAGAMET	4024271	MAY 17, 1994		D-14	MAR 31, 1991
		3950333	APR 13, 1993		D-12	APR 30, 1989
18891 001	CLONIDINE; CATAPRES-TTS-1	4201211	MAY 06, 1997			
		4060084	JUN 28, 1994			
		3996934	JUL 29, 1992			
18891 002	CLONIDINE; CATAPRES-TTS-2	4201211	MAY 06, 1997			
		4060084	JUN 28, 1994			
		3996934	JUL 29, 1992			
18891 003	CLONIDINE; CATAPRES-TTS-3	4201211	MAY 06, 1997			
		4060084	JUN 28, 1994			
		3996934	JUL 29, 1992			
19201 001	DICLOFENAC SODIUM; VOLTAREN	3652762	MAR 28, 1989		NCE	JUL 28, 1993
19201 002	DICLOFENAC SODIUM; VOLTAREN	3652762	MAR 28, 1989		NCE	JUL 28, 1993
19201 003	DICLOFENAC SODIUM; VOLTAREN	3652762	MAR 28, 1989		NCE	JUL 28, 1993
18998 001	ENALAPRIL MALEATE; VASOTEC				I-74	JUN 24, 1991
18998 002	ENALAPRIL MALEATE; VASOTEC				I-74	JUN 24, 1991
18998 003	ENALAPRIL MALEATE; VASOTEC				I-74	JUN 24, 1991
18998 005	ENALAPRIL MALEATE; VASOTEC	4374829	FEB 22, 2000		NCE	DEC 24, 1990
					I-74	JUN 24, 1991

	APPL/PROD	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19309 001	ENALAPRILAT; VASOTEC	4374829	FEB 22, 2000		NDF	FEB 09, 1991
	18981 002	ENCAINIDE HYDROCHLORIDE; ENKAID	RE30811	DEC 20, 1996	U-32		
	18981 003	ENCAINIDE HYDROCHLORIDE; ENKAID	RE30811	DEC 20, 1996	U-32		
	18981 004	ENCAINIDE HYDROCHLORIDE; ENKAID	RE30811	DEC 20, 1996	U-32		
	19386 001	ESMOLOL HYDROCHLORIDE; BREVIBLOC	4593119	JUN 03, 2003		NCE	DEC 31, 1991
			4387103	JUN 07, 2000	U-16		
>ADD>	19462 001	FAMOTIDINE; PEPCID				I-80	OCT 17, 1991
>ADD>	19462 002	FAMOTIDINE; PEPCID				I-80	OCT 17, 1991
>ADD>	19510 001	FAMOTIDINE; PEPCID				I-80	OCT 17, 1991
>ADD>	19527 001	FAMOTIDINE; PEPCID				I-80	OCT 17, 1991
	18830 003	FLECAINIDE ACETATE; TAMBOCOR	4005209	JAN 25, 1996		NS	JUN 03, 1991
			3900481	AUG 19, 1992		NCE	OCT 31, 1990
	18830 004	FLECAINIDE ACETATE; TAMBOCOR	4005209	JAN 25, 1996			
			3900481	AUG 19, 1992		NCE	OCT 31, 1990
	19452 001	FLUOCINOLONE ACETONIDE; DERMA-SMOOTHE/FS				NDF	FEB 03, 1991
	18936 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4683235	JUL 28, 2004	U-30		
			4647591	MAR 03, 2004	U-28		
			4647591	MAR 03, 2004	U-29		
			4626549	DEC 02, 2003	U-26		
			4626549	DEC 02, 2003	U-27		
			4194009	APR 19, 1994			
>ADD>	18766 002	FLURBIPROFEN; ANSAID	3793457	FEB 19, 1993		NCE	DEC 31, 1991
>ADD>			3755427	AUG 28, 1990		NDF	OCT 31, 1991
>ADD>	18766 003	FLURBIPROFEN; ANSAID	3793457	FEB 19, 1993		NCE	DEC 31, 1991
>ADD>			3755427	AUG 28, 1990		NDF	OCT 31, 1991
	19404 001	FLURBIPROFEN SODIUM; OCUFEN	3793457	FEB 19, 1993			
	19596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	4647447	MAR 03, 2004		NCE	JUN 02, 1993
	18422 001	GEMFIBROZIL; LOPID	3674836	JAN 04, 1993			
	18422 002	GEMFIBROZIL; LOPID	3674836	JAN 04, 1993			
	18061 001	HYDROCHLOROTHIAZIDE; TIMOLIDE 10-25	3655663	APR 11, 1989		D-2	FEB 03, 1991
	19129 003	HYDROCHLOROTHIAZIDE; MAXZIDE-25				D-15	MAY 13, 1991
	18956 002	IOHEXOL; OMNIPAQUE 240				I-19	JUL 29, 1991
						I-60	JUL 29, 1991
						I-75	JUL 29, 1991
						I-76	JUL 29, 1991
						I-77	JUL 29, 1991

	APPL/PROD	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18956 003	IOHEXOL; OMNIPAQUE 300	4021481	MAY 03, 1994		I-55	FEB 01, 1988
						I-58	FEB 01, 1988
						I-60	JUL 29, 1991
						I-77	JUL 29, 1991
	18956 004	IOHEXOL; OMNIPAQUE 350				I-56	MAY 24, 1991
						I-77	JUL 29, 1991
	19085 001	IPRATROPIUM BROMIDE; ATROVENT	3681500	AUG 01, 1991		NCE	DEC 29, 1991
	08107 001	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				ODE	AUG 31, 1995
						I-79	AUG 31, 1995
	08107 002	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				ODE	AUG 31, 1995
						I-79	AUG 31, 1995
	08107 003	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				ODE	AUG 31, 1995
						I-79	AUG 31, 1995
	08107 004	LEUCOVORIN CALCIUM; LEUCOVORIN CALCIUM				ODE	AUG 31, 1995
						I-79	AUG 31, 1995
	19777 001	LISINOPRIL; ZESTRIL	4374829	FEB 22, 2000		NCE	DEC 29, 1992
	19777 002	LISINOPRIL; ZESTRIL	4374829	FEB 22, 2000		NCE	DEC 29, 1992
	19777 003	LISINOPRIL; ZESTRIL	4374829	FEB 22, 2000		NCE	DEC 29, 1992
	19487 001	LOPERAMIDE HYDROCHLORIDE; IMODIUM A-D	3714159	JAN 30, 1990			
	19643 003	LOVASTATIN; MEVACOR	4231938	NOV 04, 1999		NCE	AUG 31, 1992
	18006 001	MECLOFENAMATE SODIUM; MECLOMEN				I-68	AUG 30, 1991
	18006 002	MECLOFENAMATE SODIUM; MECLOMEN				I-68	AUG 30, 1991
>ADD>	08085 002	METHOTREXATE SODIUM; METHOTREXATE				I-81	OCT 31, 1991
	11719 001	METHOTREXATE SODIUM; METHOTREXATE				ODE	APR 07, 1995
						I-78	APR 07, 1995
	11719 003	METHOTREXATE SODIUM; METHOTREXATE				ODE	APR 07, 1995
						I-78	APR 07, 1995
	11719 006	METHOTREXATE SODIUM; METHOTREXATE				ODE	APR 07, 1995
						I-78	APR 07, 1995
	11719 007	METHOTREXATE SODIUM; METHOTREXATE LPF				ODE	APR 07, 1995
						I-78	APR 07, 1995
	11719 009	METHOTREXATE SODIUM; METHOTREXATE				ODE	APR 07, 1995
						I-78	APR 07, 1995
	09048 001	METHOXSALEN; 8-MOP				I-72	MAR 23, 1991
	18654 001	MIDAZOLAM HYDROCHLORIDE; VERSED	4280957	DEC 20, 1999		NCE	DEC 20, 1990
	18654 002	MIDAZOLAM HYDROCHLORIDE; VERSED	4280957	DEC 20, 1999		NCE	DEC 20, 1990

	APPL/PROD	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19501 001	MINOXIDIL; ROGAINE				NDF	AUG 17, 1991
	19516 002	MORPHINE SULFATE; MS CONTIN				NDF	MAY 29, 1990
	18677 001	NABILONE; CESAMET	4087545	MAY 02, 1997	U-7		
	19599 001	NAFTIFINE HYDROCHLORIDE; NAFTIN	4282251	AUG 04, 1998		NCE	MAR 01, 1993
	19508 001	NIZATIDINE; AXID	4760075	MAY 03, 2000	U-33		
			4382090	MAY 03, 2000	U-33		
			4375547	MAR 01, 2000		NCE	APR 12, 1993
	19508 002	NIZATIDINE; AXID	4760075	MAY 03, 2000	U-33		
			4382090	MAY 03, 2000	U-33		
			4375547	MAR 01, 2000		NCE	APR 12, 1993
>ADD>	19667 001	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2000		NCE	OCT 21, 1993
>ADD>	19667 002	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2000		NCE	OCT 21, 1993
>ADD>	19667 003	OCTREOTIDE ACETATE; SANDOSTATIN	4395403	JUL 26, 2000		NCE	OCT 21, 1993
	19009 001	PIRBUTEROL ACETATE; MAXAIR	4175128	NOV 20, 1996			
			3786160	JAN 15, 1993			
			3700681	OCT 24, 1989		NCE	DEC 30, 1991
	19561 003	POTASSIUM CHLORIDE; MICRO-K LS	4259315	MAR 31, 1998			
>ADD>	19647 001	POTASSIUM CITRATE; POTASSIUM CITRATE				ODE	AUG 30, 1992
>ADD>	19647 002	POTASSIUM CITRATE; POTASSIUM CITRATE				ODE	AUG 30, 1992
	17535 002	PROBUCOL; LORELCO	3862332	JAN 21, 1992			
	17881 001	TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT; TECHNETIUM TC 99M	3872226	MAR 18, 1992			
			3863004	JAN 28, 1992	U-31		
	19057 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000	U-5	NCE	AUG 07, 1992
			4112097	SEP 05, 1995	U-5		
			4026894	MAY 31, 1994			
	19057 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000	U-5	NCE	AUG 07, 1992
			4112097	SEP 05, 1995	U-5		
			4026894	MAY 31, 1994			
	19057 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000	U-5	NCE	AUG 07, 1992
			4112097	SEP 05, 1995	U-5		
			4026894	MAY 31, 1994			
	19057 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000	U-5	NCE	AUG 07, 1992
			4112097	SEP 05, 1995	U-5		
	19057 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	4026894	MAY 31, 1994			
	19641 001	TERCONAZOLE; TERAZOL 3	4358449	NOV 09, 1999		NCE	DEC 31, 1992
						NDF	MAY 24, 1991

APPL/PROD	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19569 001	TIOPRONIN; TIOPRONIN				NCE	AUG 11, 1993
					ODE	AUG 11, 1995
18207 003	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 24, 1998			
		4215104	JUL 29, 1997			
19049 001	TRETINOIN; RETIN-A	3906108	SEP 16, 1992			
		3729568	APR 24, 1990			
19415 002	UROFOLLITROPIN; METRODIN				I-73	MAR 01, 1991
18817 003	VERAPAMIL HYDROCHLORIDE; CALAN				I-50	DEC 16, 1989
					I-51	DEC 16, 1989
18817 004	VERAPAMIL HYDROCHLORIDE; CALAN				I-50	DEC 16, 1989
					I-51	DEC 16, 1989

80

END

10-14-91